Antibody combination specifically binding to trail or fasl, and bispecific antibody
Patent Information
- Application Number
- MYPI2025002404
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-10-12
- Publication Date
- 2024-04-20
AI Technical Summary
There are no monoclonal antibodies targeting TRAIL and bispecific antibody drugs targeting both TRAIL and FasL yet on the market, which cannot effectively solve diseases related to the TRAIL and FasL signaling pathways.
Develop antibody combinations and bispecific antibodies that specifically bind TRAIL or FasL, including specific antibody variants and antigen-binding fragments, for the treatment of diseases related to TRAIL and FasL signaling pathways.
It provides targeted treatment options for TRAIL and FasL signaling pathways, which can effectively prevent and treat diseases related to TRAIL and FasL signaling pathways, such as inflammatory diseases, autoimmune diseases, transplant-related diseases and liver diseases.
Smart Images

Figure PI2025002404_DRAWING_001 
Figure PI2025002404_DRAWING_002 
Figure PI2025002404_DRAWING_003
Abstract
Description
Antibody combinations and bispecific antibodies that specifically bind to TRAIL or FasL
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to PCT application No. PCT / CN2022 / 126336, application date 2022.10.20, and invention name “Antibody combinations and bispecific antibodies that specifically bind to TRAIL or FasL”, and the entire contents of that application are incorporated herein by reference.
[0003] Reference to an electronic sequence listing
[0004] The contents of the electronic sequence listing (text name: CN_20220714_SEQLIST.xml, recording date: 2023.09.14, size: 219KB) are incorporated into this application by reference in its entirety. Technical Field
[0005] The present application relates to antibodies that specifically bind to TRAIL, bispecific antibodies that specifically bind to TRAIL and FasL, and pharmaceutical compositions comprising antibodies that specifically bind to TRAIL and antibodies that specifically bind to FasL and / or bispecific antibodies, as well as preparation methods and uses thereof. Background Art
[0006] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein of the TNF superfamily. It can be cleaved from the cell surface by caspases and matrix metalloproteinase-2 (MMP-2), producing a soluble form that retains pro-apoptotic activity (Wiley, SR et al. Immunity vol. 3, 6 (1995): 673-82.; Mariani, SM, and PH Krammer. European journal of immunology vol. 28, 3 (1998): 973-82.). TRAIL is constitutively present in various tissues but is primarily expressed in natural killer (NK) cells and macrophages (Wang, S. Current medicinal chemistry vol. 17, 29 (2010): 3309-17).
[0007] TRAIL has five different receptors: TRAIL-R1, TRAIL-R2, DcR1, DcR2, and osteoprotegerin. TRAIL-R1 (also known as DR4) and TRAIL-R2 (also known as DR5) contain a cytoplasmic region called the death domain, which allows the receptors to trigger cytotoxic signals upon binding to their cognate ligands. DcR1 lacks a death domain, while DcR2 contains an incomplete death domain. Osteoporegrin is a soluble TRAIL receptor. These three receptors can act as decoy receptors, blocking TRAIL from binding to its pro-apoptotic receptors or interfering with death receptor-mediated death signals, thereby preventing apoptosis (Walczak, H, and PH Krammer. Experimental Cell Research vol. 256, 1 (2000): 58-66). DR4 is commonly expressed in most human tissues, including the spleen, thymus, liver, peripheral blood leukocytes, activated T cells, and the small intestine. DR5 is ubiquitously expressed in normal and tumor tissues, but is particularly abundant in the spleen, peripheral blood leukocytes, and activated lymphocytes (Wang, S. Current medicinal chemistry vol. 17, 29 (2010): 3309-17).
[0008] After TRAIL binds to death receptors DR4 or DR5, it can induce receptor trimerization and recruit Fas-associated protein (FADD) and membrane-proximal caspase (caspase 8 or 10) to form a receptor complex known as the death-inducing signaling complex (DISC). Caspase is synthesized in an inactive zymogen form and induces its own activation after recruiting to form the DISC. Subsequently, the activated caspase directly cuts downstream effector caspases (caspase 3, 6, and 7), leading to their activation. Activated caspase 3 can cut a variety of cellular proteins and thus lead to apoptosis (Ashkenazi, A, and VM Dixit. Science (New York, NY) vol. 281, 5381 (1998): 1305-8.). In type I cells, a relatively large amount of DISC rapidly assembles and internalizes, producing enough caspase 8 (or 10) and transmitting signals to promote cell death. In contrast, in type II cells, DISC formation is delayed and less efficient. Therefore, the activation of caspase 8 in type II cells is not sufficient to activate apoptosis. The execution of apoptosis requires mitochondria to mediate the cleavage of the BH3-interacting domain death agonist (Bid) by caspase 8 to produce a truncated form of Bid (tBid), which further induces the activation of Bax and Bak in mitochondria. Activated Bax and Bak promote the loss of mitochondrial membrane potential and the release of cytochrome c, thereby leading to apoptosis (Barnhart, Bryan C et al. Seminars in immunology vol. 15, 3 (2003): 185-93.; Kohlhaas, Susan L et al. The Journal of biological chemistry vol. 282, 17 (2007): 12831-41.).
[0009] In addition to inducing cell death, TRAIL signaling can also promote cell development, survival, and proliferation by activating nuclear factor-κB (NF-κB), MAP kinase (MAPK), and Akt (Lin, Y et al. Molecular and cellular biology vol. 20, 18 (2000): 6638-45.; Lee, Tae-Jin et al. Biochemical and biophysical research communications vol. 351, 4 (2006): 1024-30.). For example, TRAIL can trigger the formation of a cytoplasmic complex containing FADD, TNF receptor-associated factor 2 (TRAF2), and NF-κB essential modifier (NEMO), which may lead to the activation of other signaling pathways, including NF-κB and MAPK activation, as well as the production of proinflammatory cytokines and chemokines.
[0010] Fas ligand (FasL) is also a type II transmembrane protein of the TNF superfamily, with 28% homology to TRAIL (Rossin, Aurélie et al. Cancers vol. 11, 5 639.8 May. 2019, doi: 10.3390 / cancers11050639). After binding to its death receptor, FasL triggers a cascade reaction similar to TRAIL, recruiting FADD and caspase 8 or caspase 10 to form a receptor complex and transmit signals to promote cell death. In type II cells, a mitochondria-dependent pathway involving Bid cleavage and cytochrome C release can also be activated and induce apoptosis (Yin, Xiao-Ming, and Wen-Xing Ding. Current molecular medicine vol. 3, 6 (2003): 491-508.).
[0011] Studies have shown that FASL and TRAIL, as ligands for death receptors, are associated with the development and progression of a variety of diseases. Yin et al.'s research has shown that death receptor-induced hepatocyte apoptosis contributes to the development of a variety of liver diseases, including viral hepatitis, inflammatory hepatitis, Wilson's disease, alcoholic liver disease, endotoxemia-induced liver failure, and ischemia / reperfusion-induced liver injury (Yin, Xiao-Ming, and Wen-Xing Ding. Current molecular medicine vol. 3, 6 (2003): 491-508). Ochi et al.'s research has shown that administering anti-TRAIL antibodies alone can partially inhibit the hepatotoxicity caused by hepatic NK cells, and combining them with anti-FasL monoclonal antibodies and perforin inhibitors can completely inhibit the hepatotoxicity (Ochi, Makoto et al. Hepatology (Baltimore, Md.) vol. 39, 5 (2004): 1321-31). Research by Zhang et al. has shown that TRAIL and FasL can participate in cell-mediated cytotoxicity through death domain-mediated apoptotic signaling in host-versus-graft disease after renal transplantation (Zhang, Yun et al. Immunology letters vol. 152, 1 (2013): 1-7). Research by Tasew et al. has shown that cells expressing FasL and TRAIL are present in the dermis of ulcerative cutaneous leishmaniasis (CL), and that inhibition of FasL and TRAIL can reduce leishmaniasis-induced skin ulcers (Tasew, Geremew et al. PLoS neglected tropical diseases vol. 4, 10e844. 12 Oct. 2010). Therefore, the development of new antibodies that bind to TRAIL or FasL, or bispecific antibodies that simultaneously bind to TRAIL and FasL, as well as pharmaceutical compositions comprising antibodies that bind to TRAIL and / or FasL, is of great importance in the medical field.
[0012] Currently, there are reports on FasL or TRAIL inhibitors. For example, Chinese Patent CN108290950B discloses the anti-FasL antibody 119-4A (used as a control antibody in the Examples section of this application) and its use; Chinese Patent CN108997503B discloses the fusion protein sDR5-Fc (used as a control in the Examples section of this application) that has the function of blocking the TRAIL-DR5 signaling pathway. However, there are no monoclonal antibodies targeting TRAIL or bispecific antibody drugs that simultaneously target TRAIL and FasL on the market. Therefore, there is an urgent need to develop monoclonal antibodies targeting TRAIL and bispecific antibody drugs that simultaneously target TRAIL and FasL.
[0013] The disclosures of all publications, patents, patent applications, and published patent applications mentioned in this application are hereby incorporated by reference in their entirety.
[0014] Application Overview
[0015] In one aspect, the present application provides an isolated antibody or antigen-binding fragment that specifically binds to TRAIL. In some embodiments, the present application provides an isolated antibody or antigen-binding fragment that specifically binds to TRAIL, comprising: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
[0016] In some embodiments, an isolated antibody or antigen-binding fragment that specifically binds to TRAIL is provided, comprising: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0017] In some embodiments, an isolated antibody or antigen-binding fragment that specifically binds to TRAIL is provided, comprising: H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 13-14 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 13-14; and V L, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 22-27 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22-27.
[0018] In some embodiments, there is provided an isolated antibody or antigen-binding fragment that specifically binds to TRAIL, comprising: (i) V H , comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 22; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 23; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 24; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 25 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 25; (v) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 26 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 26; or (vi) V H, comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 27 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 27.
[0019] In some embodiments, the present application provides an isolated antibody or antigen-binding fragment that specifically binds to TRAIL, comprising: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
[0020] In some embodiments, an isolated antibody or antigen-binding fragment that specifically binds to TRAIL is provided, comprising: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0021] In some embodiments, an isolated antibody or antigen-binding fragment that specifically binds to TRAIL is provided, comprising: H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 15-21 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 15-21; and V L, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 28-32 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28-32.
[0022] In some embodiments, there is provided an isolated antibody or antigen-binding fragment that specifically binds to TRAIL, comprising: (i) V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 28; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (v) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (vi) V H, comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (vii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (x) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xi) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xii) V H, comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xiii) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xiv) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xv) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xvi) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; or (xvii) V H , comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 21; and V L , comprising the amino acid sequence of SEQ ID NO: 32 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 32.
[0023] In some embodiments, there is provided an isolated antibody or antigen-binding fragment that specifically binds to TRAIL that competes with any of the above-described isolated antibodies for specific binding to TRAIL. In some embodiments, there is provided an isolated antibody or antigen-binding fragment that specifically binds to TRAIL that specifically binds to the same epitope as any of the above-described isolated antibodies.
[0024] In certain embodiments, any one of the antibodies specifically binding TRAIL of separation as described above comprises an Fc region. In certain embodiments, the antibody specifically binding TRAIL of the separation is a full-length IgG antibody. In certain embodiments, the antibody specifically binding TRAIL of the separation is a full-length IgG1, IgG2, IgG3 or IgG4 antibody. In certain embodiments, the antibody specifically binding TRAIL of the separation is a chimeric, fully human or humanized antibody. In certain embodiments, the antibody specifically binding TRAIL of the separation is an antigen binding fragment selected from Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody and linear antibody.
[0025] In some embodiments, an isolated nucleic acid molecule is provided, the nucleic acid molecule encoding any of the antibodies or antigen-binding fragments that specifically bind to TRAIL as described above. In some embodiments, a vector is provided, the vector comprising any of the nucleic acid molecules as described above. In some embodiments, a host cell is provided, the host cell comprising any of the antibodies or antigen-binding fragments that specifically bind to TRAIL as described above, any of the nucleic acid molecules as described above, or any of the vectors as described above. In some embodiments, a method for preparing an antibody or antigen-binding fragment that specifically binds to TRAIL is provided, comprising: a) culturing any of the host cells described above under conditions that effectively express the antibody or antigen-binding fragment that specifically binds to TRAIL; and b) obtaining the expressed antibody from the host cell.
[0026] In some embodiments, pharmaceutical compositions, kits, and articles of manufacture are provided that comprise any of the antibodies or antigen-binding fragments that specifically bind to TRAIL as described above.
[0027] In some embodiments, a method for treating a desired individual disease or condition is provided, comprising administering to the individual an effective amount of any antibody or antigen-binding fragment as described above that specifically binds to TRAIL, or a pharmaceutical composition comprising the same. In some embodiments, the use of any antibody or antigen-binding fragment as described above that specifically binds to TRAIL in the preparation of a pharmaceutical composition for treating a desired individual disease or condition is provided. In some embodiments, the use of any antibody or antigen-binding fragment as described above that specifically binds to TRAIL, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating a desired individual disease or condition is provided. In some embodiments, the disease or condition is associated with the TRAIL signaling pathway, including inflammatory diseases, autoimmune diseases, transplant-related diseases, liver diseases, neurodegenerative diseases, or cancer. In some embodiments, the disease or condition is selected from, for example, transplant rejection, graft-versus-host disease, liver injury, pulmonary hypertension, Alzheimer's disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute lung injury, acute respiratory distress syndrome, myocardial infarction, cardiomyopathy, ischemia-reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, non-alcoholic steatohepatitis, cirrhosis, drug-induced liver injury / failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, and cancer.
[0028] On the other hand, the present application provides bispecific antibodies that specifically bind to TRAIL and FasL, as well as pharmaceutical compositions comprising bispecific antibodies that specifically bind to TRAIL and FasL. In some embodiments, the present application also provides methods for preventing and / or treating diseases associated with the TRAIL and / or FasL signaling pathway using the above-mentioned bispecific antibodies or their pharmaceutical compositions. In other embodiments, the present application also provides the use of the above-mentioned bispecific antibodies or their pharmaceutical compositions in the preparation of medicaments for preventing and / or treating diseases associated with the TRAIL and / or FasL signaling pathway.
[0029] In some embodiments, the present application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL, and a second antigen-binding domain that specifically binds to FasL, wherein the first antigen-binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and VL , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; or (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 161, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the second antigen binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or (ii) V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0030] In some embodiments, the present application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL, and a second antigen-binding domain that specifically binds to FasL, wherein the second antigen-binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0031] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L LCDR1, LCDR2 and LCDR3 included; or (ii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L LCDR1, LCDR2 and LCDR3 included; or (iii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 164 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 168 L LCDR1, LCDR2 and LCDR3 included; or (iv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 166 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 170L Contains LCDR1, LCDR2 and LCDR3.
[0032] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 13-20, 33-40, 164 and 166, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 13-20, 33-40, 164 and 166; and V L , the V L The invention also provides a method for preparing a polynucleotide sequence comprising an amino acid sequence shown in any one of SEQ ID NOs: 22-31, 41-50, 168 and 170, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22-31, 41-50, 168 and 170.
[0033] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: (i) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 13 and 33 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 13 and 33; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41; (ii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42; (iii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43; (iv) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 25 and 44 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 25 and 44; (v) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 26 and 45 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 26 and 45; (vi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 27 and 46 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 27 and 46; (vii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47; (viii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48; (ix) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48; (x) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48; (xi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48; (xii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48; (xiii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (xiv) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (xv) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (xvi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (xvii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (xviii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (xix) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 17 and 37; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (xx) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 18 and 38; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (xxi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 19 and 39; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (xxii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (xxiii) V H , comprising the amino acid sequence of SEQ ID NO: 164 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 164; and V L, which comprises the amino acid sequence shown in SEQ ID NO: 168 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 168; or (xxiv) V H , comprising the amino acid sequence of SEQ ID NO: 166 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 166; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 170 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 170.
[0034] In some embodiments, according to any bispecific antibody described herein, the second antigen binding domain comprises: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 73 L LCDR1, LCDR2 and LCDR3 included; or (ii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 66 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 76 L LCDR1, LCDR2 and LCDR3 included; or (iii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 163 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 167 L LCDR1, LCDR2 and LCDR3 included; or (iv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 165 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 169 L Contains LCDR1, LCDR2 and LCDR3.
[0035] In some embodiments, according to any bispecific antibody described herein, the second antigen binding domain comprises: VH , the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 63-72, 80-88, 163 and 165, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 63-72, 80-88, 163 and 165; and V L , the V L The invention also relates to a polypeptide comprising an amino acid sequence as shown in any one of SEQ ID NOs: 73-79, 89-95, 167 and 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 73-79, 89-95, 167 and 169.
[0036] In some embodiments, according to any bispecific antibody described herein, the second antigen binding domain comprises: (i) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 63 and 80 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 63 and 80; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 73 and 89 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 73 and 89; (ii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90; (iii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 65 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 65 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90; (iv) V H, comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 75 and 91 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 75 and 91; (v) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 65 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 65 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 75 and 91 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 75 and 91; (vi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92; (vii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (viii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (ix) V H, comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (x) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (xi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (xii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 77 and 93; (xiii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xiv) V H, comprising the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xv) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xvi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xvii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xviii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94; (xix) V H, comprising the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 67 and 83; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xx) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 68 and 84; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xxi) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xxii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xxiii) V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 71 and 87; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xxiv) V H, comprising the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 72 and 88; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (xxv) V H , comprising the amino acid sequence of SEQ ID NO: 163 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 163; and V L , which comprises the amino acid sequence of SEQ ID NO: 167 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 167; or (xxvi) V H , comprising the amino acid sequence of SEQ ID NO: 165 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 165; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 169.
[0037] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V LIt comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61.
[0038] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0039] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61.
[0040] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0041] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 161, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the VL comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0042] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42, or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90.
[0043] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43, or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90.
[0044] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47, or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92.
[0045] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L, comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50, or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92.
[0046] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50, or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95.
[0047] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence of SEQ ID NO: 164 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 164; and V L , comprising the amino acid sequence of SEQ ID NO: 168 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 168; and wherein said second antigen binding domain comprises: VH , comprising the amino acid sequence of SEQ ID NO: 163 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 163; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 167 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 167.
[0048] In some embodiments, according to any bispecific antibody described herein, the first antigen binding domain comprises: V H , comprising the amino acid sequence of SEQ ID NO: 166 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 166; and V L , comprising the amino acid sequence of SEQ ID NO: 170 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 170; and wherein said second antigen binding domain comprises: V H , comprising the amino acid sequence of SEQ ID NO: 165 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 165; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 169.
[0049] In some embodiments, the bispecific antibodies described herein comprise an Fc. In other embodiments, the Fc described herein is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD. In some embodiments, the Fc comprises an Fc variant. In some embodiments, the Fc is glycosylated. In some embodiments, the Fc is deglycosylated. In some embodiments, the Fc has reduced fucosylation or is afucosylated. In some embodiments, the Fc variant comprises a substitution at one or more of positions 228, 239, 282, 289, 297, 312, 324, 330, 335, 337, 339, 356, 359, 361, 383, 384, 398, 400, 440, 422, and 442, numbered according to the EU index. In some embodiments, the Fc variant comprises a substitution at position 297. In some embodiments, the substitution at position 297 is 297Q.
[0050] In some embodiments, the bispecific antibody has a DVD-Ig structure. In some embodiments, the bispecific antibody comprises four polypeptide chains: wherein,
[0051] Both polypeptide chains contain V from N-terminus to C-terminus H 1-LV H 2-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to TRAIL; V H 2 is the heavy chain variable region that specifically binds to FasL; L is the connecting peptide; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains;
[0052] The other two polypeptide chains contain V L 1-LV L 2-C L structure, where V L 1 is the light chain variable region that specifically binds to TRAIL; V L 2 is the light chain variable region that specifically binds to FasL; L is the connecting peptide; C L is the light chain constant region;
[0053] Among them, V H 1 and V L 1 constitutes an antigen binding domain (Fv) that can specifically bind to TRAIL, V H 2-C H 1 and V L 2-C L It consists of an antigen-binding domain (Fab) that can specifically bind to FasL.
[0054] In other embodiments, the bispecific antibody comprises four polypeptide chains:
[0055] Both polypeptide chains contain V H 1-LV H 2-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; V H 2 is the heavy chain variable region that specifically binds to TRAIL; L is the connecting peptide; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains;
[0056] The other two polypeptide chains contain V L 1-LV L 2-C L structure, where V L 1 is the light chain variable region that specifically binds to FasL; V L 2 is the light chain variable region that specifically binds to TRAIL; L is the connecting peptide; C L is the light chain constant region;
[0057] Among them, V H 1 and V L 1 constitutes an antigen binding domain (Fv) that can specifically bind to FasL, V H 2-C H 1 and V L 2-C L It consists of an antigen binding domain (Fab) that can specifically bind to TRAIL.
[0058] In some embodiments, the bispecific antibodies described herein comprise: (a) the amino acid sequence of SEQ ID NO: 104 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 104; and / or the amino acid sequence of SEQ ID NO: 105 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 105; (b) the amino acid sequence of SEQ ID NO: 104 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 104; and / or the amino acid sequence of SEQ ID NO: 106 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 106; (c) the amino acid sequence of SEQ ID NO: 107 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 107; and / or the amino acid sequence of SEQ ID NO: 108 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 108; (d) the amino acid sequence of SEQ ID NO: NO: 107 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 107; and / or the amino acid sequence of SEQ ID NO: 109 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 109; (e) the amino acid sequence of SEQ ID NO: 110 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 110; and / or the amino acid sequence of SEQ ID NO: 111 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 111; or (f) the amino acid sequence of SEQ ID NO: 172 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 172; and / or the amino acid sequence of SEQ ID NO: 174 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 174).
[0059] In some embodiments, the bispecific antibodies described herein comprise: (a) the amino acid sequence of SEQ ID NO: 131 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and / or the amino acid sequence of SEQ ID NO: 105 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105; (b) the amino acid sequence of SEQ ID NO: 131 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and / or the amino acid sequence of SEQ ID NO: 106 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106; (c) the amino acid sequence of SEQ ID NO: 132 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132; and / or the amino acid sequence of SEQ ID NO: 108 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; (d) the amino acid sequence of SEQ ID NO: NO: 132 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 132; and / or the amino acid sequence of SEQ ID NO: 109 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 109; (e) the amino acid sequence of SEQ ID NO: 133 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 133; and / or the amino acid sequence of SEQ ID NO: 111 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 111; or (f) the amino acid sequence of SEQ ID NO: 176 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 176; and / or the amino acid sequence of SEQ ID NO: 174 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 174.
[0060] In other embodiments, the bispecific antibodies described herein have a Bs4Ab structure. In some embodiments, the bispecific antibodies comprise four polypeptide chains:
[0061] The two polypeptide chains contain V from N-terminus to C-terminus H 1-C H 1-L1-V H 2-L3-V L 2 structure or V H 1-CH 1-L1-V L 2-L3-V H 2 structure, where V H 1 is the heavy chain variable region that specifically binds to TRAIL; V H 2 is the heavy chain variable region that specifically binds to FasL, V L 2 is the light chain variable region that specifically binds to FasL; L1 and L3 are connecting peptides; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and
[0062] The other two polypeptide chains contain V L 1-C L structure, where V L 1 is the light chain variable region that specifically binds to TRAIL, C L is the light chain constant region.
[0063] Among them, V H 1-C H 1 and V L 1-C L Composition of the antigen binding domain (Fab) that specifically binds to TRAIL, V H 2-L3-V L 2 or V L 2-L3-V H 2 constitutes an antigen binding domain (scFv) that specifically binds to FasL.
[0064] In some embodiments, the bispecific antibody comprises four polypeptide chains:
[0065] The two polypeptide chains contain V from N-terminus to C-terminus H 1-C H 1-L1-V H 2-L3-V L 2 structure or V H 1-C H 1-L1-V L 2-L3-V H 2 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; V H 2 is the heavy chain variable region that specifically binds to TRAIL, V L 2 is the light chain variable region that specifically binds to TRAIL; L1 and L3 are connecting peptides; C H 1 is the heavy chain constant region C H1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and
[0066] The other two polypeptide chains contain V L 1-C L structure, where V L 1 is the light chain variable region that specifically binds to FasL, C L is the light chain constant region.
[0067] Among them, V H 1-C H 1 and V L 1-C L Composition of the antigen binding domain (Fab) that specifically binds to FasL, V H 2-L3-V L 2 or V L 2-L3-V H 2 constitutes an antigen binding domain (scFv) that specifically binds to TRAIL.
[0068] In some embodiments, the bispecific antibody comprises: (a) the amino acid sequence of SEQ ID NO: 112 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 112; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; (b) the amino acid sequence of SEQ ID NO: 114 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 114; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; (c) the amino acid sequence of SEQ ID NO: 116 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 116; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; (d) the amino acid sequence of SEQ ID NO: NO: 117 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 117; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 119; (e) the amino acid sequence of SEQ ID NO: 118 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 118; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 119; (f) the amino acid sequence of SEQ ID NO: 120 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 120; and / or the amino acid sequence of SEQ ID NO: 121 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 121; (g) the amino acid sequence of SEQ ID NO: 120 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: NO: 120 having at least about 80% sequence identity; and / or the amino acid sequence of SEQ ID NO: 122 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; (h) the amino acid sequence of SEQ ID NO: 123 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 123;and / or the amino acid sequence of SEQ ID NO: 124 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 124; or (i) the amino acid sequence of SEQ ID NO: 171 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 171; and / or the amino acid sequence of SEQ ID NO: 173 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 173.;
[0069] In some embodiments, the bispecific antibody comprises: (a) the amino acid sequence of SEQ ID NO: 134 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 134; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; (b) the amino acid sequence of SEQ ID NO: 135 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 135; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; (c) the amino acid sequence of SEQ ID NO: 136 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 136; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; (d) the amino acid sequence of SEQ ID NO: NO: 137 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 137; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 115; (e) the amino acid sequence of SEQ ID NO: 138 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 138; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 119; (f) the amino acid sequence of SEQ ID NO: 139 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 139; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 119; (g) the amino acid sequence of SEQ ID NO: 140 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: NO: 140 having at least about 80% sequence identity; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; (h) the amino acid sequence of SEQ ID NO: 141 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141;and / or the amino acid sequence of SEQ ID NO: 121 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121; (i) the amino acid sequence of SEQ ID NO: 141 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141; and / or the amino acid sequence of SEQ ID NO: 122 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; (j) the amino acid sequence of SEQ ID NO: 142 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 142; and / or the amino acid sequence of SEQ ID NO: 124 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 124; or (k) the amino acid sequence of SEQ ID NO: 175 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 175; and / or the amino acid sequence of SEQ ID NO: 173 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: NO:173 has at least about 80% sequence identity. ;
[0070] In some embodiments, the bispecific antibodies described herein have a Hetero H, CrossMab structure. In some embodiments, the bispecific antibodies comprise four polypeptide chains:
[0071] A polypeptide chain from N-terminus to C-terminus contains V H 1-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to TRAIL, C H 1 is the heavy chain constant region C H 1 domain, wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and
[0072] A polypeptide chain from N-terminus to C-terminus contains V L 1-C L , where V L 1 is the light chain variable region that specifically binds to TRAIL, C L is the light chain constant region; and
[0073] A polypeptide chain from N-terminus to C-terminus contains V H 2-C L , where V H 2 is the heavy chain variable region that specifically binds to FasL, C Lis a light chain constant region, wherein the polypeptide chain further comprises an Fc comprising a C H 2 and C H 3 domains; and
[0074] A polypeptide chain from N-terminus to C-terminus contains V L 2-C H 1, where V L 2 is the light chain variable region that specifically binds to FasL, C H 1 is the heavy chain constant region C H 1 domain.
[0075] Among them, V H 1-C H 1 and V L 1-C L Composition of the antigen binding domain (Fab) that specifically binds to TRAIL, V H 2-C L and V L 2-C H 1 constitutes the antigen binding domain (Fab) that specifically binds to FasL.
[0076] In some embodiments, the bispecific antibody comprises four polypeptide chains:
[0077] A polypeptide chain from N-terminus to C-terminus contains V H 1-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and
[0078] A polypeptide chain from N-terminus to C-terminus contains V L 1-C L , where V L 1 is the light chain variable region that specifically binds to FasL, C L is the light chain constant region; and
[0079] A polypeptide chain from N-terminus to C-terminus contains V H 2-C L , where V H 2 is the heavy chain variable region that specifically binds to TRAIL; C L is a light chain constant region; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and
[0080] A polypeptide chain from N-terminus to C-terminus contains V L 2-C H 1, where V L 2 is the light chain variable region that specifically binds to TRAIL, C H 1 is the heavy chain constant region C H 1 domain.
[0081] Among them, V H 1-C H 1 and V L 1-C L Composition of the antigen binding domain (Fab) that specifically binds to FasL, V H 2-C L and V L 2-C H 1 constitutes the antigen binding domain (Fab) that specifically binds to TRAIL.
[0082] In some embodiments, the bispecific antibody comprises: (a) the amino acid sequence of SEQ ID NO: 125 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and / or the amino acid sequence of SEQ ID NO: 126 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and / or the amino acid sequence of SEQ ID NO: 127 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 127; and / or the amino acid sequence of SEQ ID NO: 129 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129; or (b) the amino acid sequence of SEQ ID NO: 125 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and / or the amino acid sequence of SEQ ID NO: 130 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130; and / or the amino acid sequence of SEQ ID NO: NO:128 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:128; and / or the amino acid sequence of SEQ ID NO:129 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:129.
[0083] In some embodiments, the bispecific antibody comprises: (a) the amino acid sequence of SEQ ID NO: 143 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 143; and / or the amino acid sequence of SEQ ID NO: 126 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and / or the amino acid sequence of SEQ ID NO: 144 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 144; and / or the amino acid sequence of SEQ ID NO: 129 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129; or (b) the amino acid sequence of SEQ ID NO: 145 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 145; and / or the amino acid sequence of SEQ ID NO: 130 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130; and / or the amino acid sequence of SEQ ID NO: NO:146 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:146; and / or the amino acid sequence of SEQ ID NO:129 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:129.
[0084] In some embodiments, a method for treating a desired individual disease or condition is provided, comprising administering to the individual an effective amount of any bispecific antibody as described above or a pharmaceutical composition comprising the same. In some embodiments, the use of any bispecific antibody as described above in the preparation of a pharmaceutical composition for treating a desired individual disease or condition is provided. In some embodiments, the use of any bispecific antibody as described above or a pharmaceutical composition comprising the same in the preparation of a medicament for treating a disease or condition is provided. In some embodiments, the disease or condition is associated with the TRAIL and / or FasL signaling pathway, including inflammatory diseases, autoimmune diseases, transplant-related diseases, liver diseases, neurodegenerative diseases, or cancer. In some embodiments, the disease or condition is selected from, for example, transplant rejection, graft-versus-host disease, liver injury, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute lung injury, acute respiratory distress syndrome, myocardial infarction, cardiomyopathy, ischemia-reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, non-alcoholic steatohepatitis, cirrhosis, drug-induced liver injury / failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, and cancer.
[0085] In some embodiments, the present application provides an isolated nucleic acid molecule encoding any of the bispecific antibodies described above. In some embodiments, a vector is provided comprising any of the nucleic acid molecules described above. In some embodiments, a host cell is provided comprising any of the bispecific antibodies, any of the nucleic acid molecules, or any of the vectors described above. In some embodiments, a method for preparing a bispecific antibody that specifically binds to TRAIL and FasL is provided, comprising: a) culturing any of the host cells described above under conditions effective to express the bispecific antibody that specifically binds to TRAIL and FasL; and b) obtaining the expressed bispecific antibody in the host cell.
[0086] Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising any of the bispecific antibodies, nucleic acid molecules, vectors, or host cells described above.
[0087] In one aspect, the present application provides a pharmaceutical composition comprising: (i) an antibody or antigen-binding fragment that specifically binds to TRAIL, and (ii) an antibody or antigen-binding fragment that specifically binds to FasL.
[0088] In one aspect, the present application provides a method for treating and / or preventing a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of (i) an antibody or antigen-binding fragment that specifically binds to TRAIL and (ii) an antibody or antigen-binding fragment that specifically binds to FasL, or a pharmaceutical composition comprising the antibody or antigen-binding fragment that specifically binds to TRAIL and the antibody or antigen-binding fragment that specifically binds to FasL.
[0089] In another aspect, the present application provides the use of an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL in the preparation of a pharmaceutical composition for treating a desired individual disease or condition. In another aspect, the present application provides the use of an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL, or a pharmaceutical composition comprising an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL in the preparation of a medicament for treating a desired individual disease or condition.
[0090] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: (a) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or (b) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0091] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to FasL comprises: (a) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or (b) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0092] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: (a) V H, which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L LCDR1, LCDR2 and LCDR3 included; or (b) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L Contains LCDR1, LCDR2 and LCDR3.
[0093] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: (i) V H , comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 22; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 23; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 24; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, comprising the amino acid sequence of SEQ ID NO: 25 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 25; (v) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 26 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 26; (vi) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 27 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 27; (vii) V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 28; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (x) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L, comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (xi) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (xii) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29; (xiii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xiv) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xv) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xvi) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L, comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xvii) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30; (xviii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xix) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xx) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xxi) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31; (xxii) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L, comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; or (xxiii) V H , comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 21; and V L , comprising the amino acid sequence of SEQ ID NO: 32 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 32.
[0094] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to FasL comprises: (a) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 73 L LCDR1, LCDR2 and LCDR3 included; or (b) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 66 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 76 L Contains LCDR1, LCDR2 and LCDR3.
[0095] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to FasL comprises: (i) V H , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; and V L , comprising the amino acid sequence of SEQ ID NO: 73 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 73; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L, comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 74; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 74; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 75 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 75; (v) V H , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; and V L , comprising the amino acid sequence of SEQ ID NO: 75 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 75; (vi) V H , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 76; (vii) V H , comprising the amino acid sequence of SEQ ID NO: 67 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 67; and V L , comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 77; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 68 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 68; and V L, comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 77; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 77; (x) V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 77; (xi) V H , comprising the amino acid sequence of SEQ ID NO: 71 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 71; and V L , comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 77; (xii) V H , comprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 72; and V L , comprising the amino acid sequence of SEQ ID NO: 77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 77; (xiii) V H , comprising the amino acid sequence of SEQ ID NO: 67 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 67; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; (xiv) V H , comprising the amino acid sequence of SEQ ID NO: 68 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 68; and V L, comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; (xv) V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 78; (xvi) V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 78; (xvii) V H , comprising the amino acid sequence of SEQ ID NO: 71 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 71; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 78; (xviii) V H , comprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 72; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; (xix) V H , comprising the amino acid sequence of SEQ ID NO: 67 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 67; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 79; (xx) V H , comprising the amino acid sequence of SEQ ID NO: 68 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 68; and V L, comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 79; (xxi) V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 79; (xxii) V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 79; (xxiii) V H , comprising the amino acid sequence of SEQ ID NO: 71 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 71; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 79; or (xxiv) V H , comprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 72; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 79.
[0096] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; and wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0097] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; and wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0098] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; and wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0099] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; and wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0100] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H, comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74.
[0101] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74.
[0102] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 28; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: VH , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76.
[0103] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76.
[0104] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78.
[0105] In some embodiments, in the pharmaceutical compositions, methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; and wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 79.
[0106] In some embodiments, in the methods or uses described herein, the antibody or antigen-binding fragment that specifically binds to TRAIL and the antibody or antigen-binding fragment that specifically binds to FasL are administered simultaneously. In other embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL and the antibody or antigen-binding fragment that specifically binds to FasL are administered sequentially.
[0107] In some embodiments, in the pharmaceutical compositions, methods, or uses described herein, the molar ratio of the antibody or antigen-binding fragment that specifically binds to TRAIL to the antibody or antigen-binding fragment that specifically binds to FasL is about 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, or 1:5. In other embodiments, the molar ratio of the antibody or antigen-binding fragment that specifically binds to TRAIL to the antibody or antigen-binding fragment that specifically binds to FasL is about 2:1 or 1:1.
[0108] In one aspect, the present application provides a method for treating and / or preventing a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of any antibody or antigen-binding fragment and / or bispecific antibody and / or any pharmaceutical composition described herein.
[0109] In some embodiments, according to any of the methods or uses described herein, the disease or condition is associated with the TRAIL and / or FasL signaling pathway, including inflammatory diseases, autoimmune diseases, transplant-related diseases, liver diseases, neurodegenerative diseases, or cancer. In some embodiments, the disease or condition is selected from, for example, transplant rejection, graft-versus-host disease, liver injury, pulmonary hypertension, Alzheimer's disease, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, trauma, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute lung injury, acute respiratory distress syndrome, myocardial infarction, cardiomyopathy, ischemic reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, non-alcoholic steatohepatitis, cirrhosis, drug-induced liver injury / liver failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, and cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0110] FIG1 shows the results of humanized antibodies G10-1, G10-2, G72-10, and G72-11 inhibiting PBMC from killing HepG2 cells.
[0111] FIG2 shows the results of humanized antibodies G10-1, G10-2, G72-10, and G72-11 inhibiting granulocyte killing of HepG2 cells.
[0112] FIG3 shows the results of the inhibition of ALT elevation induced by APAP by the anti-TRAIL antibody G72.
[0113] Figures 4A-4B show the results of the combined application of an antibody that specifically binds to TRAIL and an antibody that specifically binds to FasL in inhibiting PBMC from killing HepG2 cells (Figure 4A) and Jurkat cells (Figure 4B).
[0114] Figure 5A shows a schematic diagram of the structure of a DVD-Ig (Dual-variable domain-Ig) bispecific antibody; Figure 5B shows a schematic diagram of the structure of a Bs4Ab bispecific antibody; Figure 5C shows a schematic diagram of the structure of a Hetero H, CrossMab bispecific antibody; Figure 5D shows a schematic diagram of the structure of an IgG-(scFv)2 bispecific antibody; and Figure 5E shows a schematic diagram of the structure of an scFv-Fab IgG bispecific antibody.
[0115] Figures 6A-6C show the results of the bispecific antibody that specifically binds to TRAIL and FasL inhibiting PBMC from killing HepG2 cells.
[0116] Figures 7A-7B show the results of the bispecific antibody that specifically binds to TRAIL and FasL inhibiting PBMC from killing Jurkat cells.
[0117] Figures 8A-8B show the results that bispecific antibodies that specifically bind to TRAIL and FasL, or the combined use of antibodies that specifically bind to TRAIL and antibodies that specifically bind to FasL inhibited the increase in ALT induced by APAP in mice.
[0118] Figures 9A-9B show the results of the bispecific antibody that specifically binds to TRAIL and FasL inhibiting the elevation of ALT (Figure 9A) and AST (Figure 9B) induced by APAP in cynomolgus monkeys.
[0119] Detailed description of this application
[0120] In one aspect, the present application provides an antibody or antigen-binding fragment that specifically binds to TRAIL. In another aspect, the present application provides a bispecific antibody that specifically binds to TRAIL and FasL. In another aspect, the present application provides a pharmaceutical composition comprising an antibody or antigen-binding fragment that specifically binds to TRAIL and / or an antibody or antigen-binding fragment that specifically binds to FasL, and a pharmaceutical composition comprising a bispecific antibody that specifically binds to TRAIL and FasL. In another aspect, the present application also provides a method for treating a desired individual disease or condition, comprising administering to the individual an effective amount of an antibody or antigen-binding fragment that specifically binds to TRAIL or a pharmaceutical composition comprising the same, a bispecific antibody that specifically binds to TRAIL and FasL or a pharmaceutical composition comprising the same, or an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL or a pharmaceutical composition comprising the same. On the other hand, the present application provides the use of an antibody or antigen-binding fragment that specifically binds to TRAIL or a pharmaceutical composition comprising the same, a bispecific antibody that specifically binds to TRAIL and FasL or a pharmaceutical composition comprising the same, or an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL or a pharmaceutical composition comprising the same in the preparation of a medicament for preventing or treating a disease or condition in an individual in need thereof.
[0121] Through a combination of scFv phage library screening, affinity maturation, and appropriately designed biochemical and biological experiments, antibodies or antigen-binding fragments that specifically bind to TRAIL and antibodies or antigen-binding fragments that specifically bind to FasL were identified. Bispecific antibodies that specifically bind to TRAIL and FasL were also prepared. When used as (i) a pharmaceutical composition, (ii) a bispecific antibody, or (iii) a combination therapy for treating a disease, these antibodies can achieve cumulative or synergistic effects, enhancing therapeutic efficacy.
[0122] The present application also provides nucleic acids encoding antibodies or antigen-binding fragments that specifically bind to TRAIL, or bispecific antibodies that specifically bind to TRAIL and FasL, compositions comprising antibodies or antigen-binding fragments that specifically bind to TRAIL and antibodies or antigen-binding fragments that specifically bind to FasL, and methods for preparing and using antibodies or antigen-binding fragments that specifically bind to TRAIL, or antibodies or antigen-binding fragments that specifically bind to FasL, or bispecific antibodies that specifically bind to TRAIL and FasL, and pharmaceutical compositions comprising any of the above antibodies or antigen-binding fragments.
[0123] definition
[0124] As described in the present application, " treatment (treatment) " or " treatment (treating) " is a method for obtaining beneficial or desired results, including clinical results. In view of the purpose of the present application, the beneficial or desired clinical results, including but not limited to the following one or more: alleviate one or more symptoms caused by the disease, alleviate the degree of disease, stabilize the disease (for example, prevent or delay disease worsening), prevent or delay the spread of the disease, prevent or delay disease recurrence, delay or slow down disease progression, improve the disease state, alleviate the disease (partial or complete), reduce the dosage of one or more other drugs required for the treatment of the disease, delay disease progression, improve or improve quality of life, gain weight, and / or prolong life. At the same time, " treatment " also includes the minimizing (for example, host cell lysis or necrosis) of infection pathology results. The method of the present application takes into account any one or more aspects of these treatments.
[0125] The term "prevent" and similar words, such as "prevented," "preventing," "prevention," or "prophylactic," refer to a method of preventing, inhibiting, or reducing the likelihood of an occurrence or recurrence of a disease or condition, such as infection by a pathogen. It also refers to delaying the occurrence or recurrence of a disease or condition, or delaying the occurrence or recurrence of a symptom of a disease or condition. As used herein, "prevention" and similar words also include reducing the intensity, impact, symptoms, and / or burden of a disease or condition before it occurs or recurs. As used herein, "prevention" and similar words also include reducing the risk and susceptibility of a disease or condition to occur or recur, such as infection by a pathogen.
[0126] Antibodies or antigen-binding fragments As described in this application, the term "antibody" is broad and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (such as bispecific antibodies), full-length antibodies and antigen-binding fragments thereof, as long as they exhibit the desired antigen-binding activity. A full-length antibody includes two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in the two chains typically include three highly variable loops, known as complementarity determining regions (CDRs), light chain (LC) CDRs include LC-CDR1, LC-CDR2 and LC-CDR3, and heavy chain (HC) CDRs include HC-CDR1, HC-CDR2 and HC-CDR3). The CDR boundaries of the antibodies or antigen-binding fragments disclosed herein may be defined or identified by the Kabat, Chothia, or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDR regions of the heavy or light chain are interposed between flanking segments called framework regions (FRs), which are more highly conserved than the CDR regions and form a scaffold that supports the hypervariable loops. The constant regions of the heavy and light chains are not involved in antigen binding but exhibit various effector functions. Antibodies are classified based on the amino acid sequence of their heavy chain constant regions. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by having heavy chains of type α, δ, ε, γ, and μ, respectively. Several major antibody classes are divided into subclasses, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain).
[0127] As used herein, the term "antigen-binding fragment" includes an antibody fragment, including, for example, a diabody, Fab, Fab', F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide-stabilized diabody (dsdiabody), a single-chain antibody (scFv), an scFv dimer (divalent diabody), a multispecific antibody composed of an antibody fragment comprising one or more CDRs, a single-domain antibody, a nanobody, a domain antibody, a divalent domain antibody, or any other antibody fragment that can bind to an antigen but does not comprise a complete antibody structure. Fab (fragment antigen-binding) as used herein is a fragment comprising the V domain of an antibody. L domain, V H domain, C Ldomain, and C H Antigen-binding fragments also include fusion proteins comprising the above-mentioned antibody fragments. Antigen-binding fragments are capable of binding to the same antigen as the parent antibody or parent antibody fragment (such as a parent scFv). In some embodiments, the antigen-binding fragment may include one or more CDRs from a specific human antibody, which are transplanted into the framework regions of one or more different human antibodies.
[0128] As described in this application, the term "bispecific antibody" refers to an antibody molecule that has binding specificity for two different antigens or epitopes in one molecule. The production process of bispecific antibodies includes the design of complete molecules, synthesis and cloning of the nucleotide sequence of each domain, expression in mammalian cells, and purification of the final product. Exemplary bispecific antibody structures include structures known in the art, for example, DVD-Ig structure, Bs4Ab structure, Hetero H, CrossMab structure, IgG-(scFv) 2 structure or scFv-Fab IgG structure (for example, see review document Labrijn AF, et al. Nat Rev Drug Discov. 2019 Aug; 18 (8): 585-608).
[0129] DVD-Ig (Dual-variable domain-Ig) bispecific antibodies are constructed by connecting the V domain of another antibody to the N-terminus of the light chain and heavy chain of a full-length IgG antibody. L and V H domain, through V H With V LThe interaction forms an antigen binding domain (Fv), and at the same time binds to the corresponding antigen to achieve bispecificity. The bispecific antibody of the exemplary DVD-Ig structure is also recorded in the document Wu C, et al.Molecular construction and optimization of anti-human IL-1alpha / beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs. 2009 Jul-Aug; 1 (4): 339-47. The Bs4Ab structure bispecific antibody is a bispecific quadrivalent antibody that includes a full-length IgG1 structure and achieves bispecificity by inserting another binding unit scFv into its hinge region. The bispecific antibody of the Bs4Ab structure is also recorded in the document Bezabeh B, et al.Insertion of scFv into the hinge domain of full-length IgG1monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs. 2017 Feb / Mar; 9 (2): 240-256. Hetero H, a bispecific antibody with a CrossMab structure, has a knobs-in-holes (KIH) structure designed in the Fc region, and introduces two Cys residue mutations that can form a stabilizing disulfide bridge (S354C on the "knob" side and Y349C on the "hole" side). CrossMab technology is also used to ensure the correct pairing between the light and heavy chains of the antibody. CrossMab technology is based on the exchange of antibody domains within a Fab arm of a bispecific IgG antibody, which can be the exchange of the entire Fab domain (CrossMAb Fab) or the exchange of only the variable region in the Fab domain (CrossMAb V H -V L ) or exchange of the constant regions only (CrossMAb C H 1-C L). The bispecific antibodies with Hetero H and CrossMab structures are also described in the literature Klein C, et al. The use of CrossMAb technology for the generation of bi-and multispecific antibodies. MAbs. 2016 Aug-Sep; 8(6): 1010-20. The bispecific antibodies with IgG-(scFv)2 structure are bispecific antibodies that connect the scFv fragment of another antibody to the Fc termini of the two heavy chains of an IgG antibody to achieve bispecificity. The bispecific antibodies with IgG-(scFv)2 structure are also described in the literature Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997 Feb; 15(2): 159-63. The scFv-Fab IgG structure bispecific antibody is a heterodimeric antibody with an IgG antibody structure, in which one of the Fab arms is replaced with a scFv structure, wherein the first monomer comprises scFv and IgG Fc, and the scFv is connected to the IgG FcC via a connecting peptide. H At the N-terminus of the 2 domains, the second monomer contains Fab and IgG Fc.
[0130] As described in this application, the term "antigen binding domain" refers to the part of an antigen binding molecule that specifically binds to an antigen. More specifically, the term "antigen binding domain" refers to a part of an antibody that includes a region that specifically binds to and is complementary to part or all of an antigen. If it is a large antigen, the antigen binding molecule may only bind to a specific part of the antigen, which is called an antigen epitope. For example, the antigen binding domain can be provided by one or more variable regions (also referred to as variable domains). Preferably, the antigen binding domain includes the variable region of the antibody light chain (V L ) and antibody heavy chain variable region (V H In one aspect, the antigen binding domain is capable of binding to its antigen and blocking or partially blocking the function of the antigen. Antigen binding domains that specifically bind to TRAIL or FasL include antibodies and antigen binding fragments as further defined herein.
[0131] As used herein, the term "epitope" refers to a specific group of atoms or amino acids on an antigen to which an antibody or antibody portion binds. If two antibodies or antibody portions exhibit competitive binding to an antigen, they likely bind to the same epitope on the antigen.
[0132] As described herein, a first antibody "competes" for binding to a second antibody for a TRAIL target when the first antibody inhibits binding of the second antibody to the TRAIL target by at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) at equimolar concentrations, and vice versa. PCT publication WO 03 / 48731 describes a high-throughput antibody "epitope binning" method based on cross-competition.
[0133] As used herein, the terms "specifically bind," "specifically recognize," or "specific for" refer to a measurable and reproducible interaction, such as the binding of a target to an antibody that can confirm the presence of the target in a heterogeneous population of molecules, including biomolecules. For example, an antibody's ability to specifically recognize a target (which may be an epitope) means that the antibody binds to the target with greater affinity, avidity, greater ease, and / or greater persistence than it binds to other targets. In some embodiments, an antibody that specifically recognizes an antigen reacts with one or more antigenic determinants of the antigen with an affinity that is at least 10 times greater than its binding affinity to other targets.
[0134] As used herein, an "isolated" antibody is an antibody that (1) is not related to naturally occurring proteins, (2) does not contain other proteins from the same source, (3) is expressed by cells of a different species, or (4) does not exist in nature.
[0135] As used herein, the term "isolated nucleic acid" refers to a nucleic acid of genomic, cDNA, or synthetic origin, or a combination thereof. Depending on its origin, the "isolated nucleic acid" (1) is unrelated to all or part of a polynucleotide found in nature, (2) is operably linked to a polynucleotide to which it is not naturally associated, or (3) does not occur in nature as part of a longer sequence.
[0136] As used herein, the term "CDR" or "complementarity determining region" refers to the non-contiguous antigen binding sites found within the variable regions of heavy and light chain polypeptides. In the literature Kabat et al., J. Biol. Chem. 252: 6609-6616 (1977); Kabat et al., USDept. of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol. 196: 901-917 (1987); Al-Lazikani B. et al. al., J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262: 732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc MPet These specific regions have been described in, for example, Desmond et al., Dev. Comp. Immunol., 27:55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), wherein these definitions include overlap or subsets of amino acid residues when compared to one another. However, any definition used to designate a CDR of an antibody or grafted antibody or variant thereof is included within the scope of the term as defined and used herein. Table 1 lists the positions of the amino acid residues included in the CDRs defined by the various references cited above for comparison. Algorithms and binding interfaces for CDR prediction are known in the art, including, for example, Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432-D438 (2015). The contents of the references cited in this paragraph are incorporated herein by reference in their entirety for use in this application and in one or more claims that may be included in this application.
[0137] Table 1: CDR Definition 1 The amino acid residue numbers refer to the nomenclature of Kabat et al.2 The amino acid residue numbers refer to the nomenclature of Chothia et al. 3 The amino acid residue numbers refer to the nomenclature of MacCallum et al. 4 The amino acid residue numbers refer to the nomenclature of Lefranc et al. 5 The amino acid residue numbers refer to the nomenclature of Honegger and Plückthun.
[0138] The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to the corresponding sequence in an antibody from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they have the biological activity described in the present application (see US Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984)).
[0139] "Fv" is the smallest antibody fragment that contains a complete antigen recognition and binding site. This fragment is a dimer formed by a heavy chain variable region and a light chain variable region tightly non-covalently linked. Six hypervariable loops (3 loops each in the light chain and heavy chain) are derived from the folding of these two domains. The hypervariable loops provide the antibody with amino acid residues for binding to the antigen and give the antibody specificity for binding to the antigen. However, even a single variable region (or half of an Fv fragment, which contains only 3 CDRs specific for the antigen) has the ability to recognize and bind to the antigen, although its affinity is lower than that of the complete binding site.
[0140] "Single-chain Fv", also abbreviated as "sFv" or "scFv", is a Fv that contains V molecules linked into a single polypeptide chain. H and V L In some embodiments, the scFv polypeptide further comprises a V H and V L The linker polypeptide between the domains allows the scFv to form an ideal structure for antigen binding. For an overview of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0141] The term "diabodies" refers to double-chain antibodies H and V L A small antibody fragment prepared by constructing an scFv fragment (see above) with a short linker (e.g., 5-10 residues) between the chains, so that the variable regions pair between the chains rather than within the chains, resulting in a bivalent fragment, that is, a fragment with two antigen-binding sites. A bispecific diabody is a heterodimer of two "crossover" scFv fragments, in which the V domains of the two antibodies are H and V L The domains are located on different polypeptide chains. Diabodies are fully described in EP 404,097; WO 93 / 11161; Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
[0142] The "humanized" form of a non-human (such as a rodent) antibody is a chimeric antibody that includes minimal sequences from a non-human antibody. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) in which the hypervariable region (HVR) residues of the recipient antibody are replaced by hypervariable region residues from a non-human species such as a mouse, rat, rabbit or non-human primate with ideal antibody specificity, affinity and performance (donor antibody). In some cases, residues in the human immunoglobulin framework region (FR) are replaced by corresponding non-human residues. In addition, a humanized antibody can include residues that are not present in either the recipient antibody or the donor antibody. These modifications can further improve the performance of the antibody. Typically, a humanized antibody will comprise essentially at least one, usually two, variable regions, in which all or substantially all of the hypervariable loops correspond to the hypervariable loops of a non-human immunoglobulin, and all or substantially all of the framework regions are human immunoglobulin sequences. The human antibody optionally also comprises at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin. For details, see Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2: 593-596 (1992).
[0143] The "percent (%) amino acid sequence identity" or "homology" of the polypeptide and antibody sequences identified herein is defined as the percentage of identical amino acid residues between a candidate sequence and the polypeptide sequence being compared, when conservative substitutions are considered part of the sequence homology. Percent amino acid sequence homology can be determined by a variety of alignment methods within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm needed to maximize alignment over the full length of the sequences being compared. However, for the purposes of this application, percent amino acid sequence homology values are generated using the sequence alignment computer program MUSCLE (Edgar, RC, Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, RC, BMC Bioinformatics 5(1):113, 2004).
[0144] The term "Fc (fragment crystallizable)" or "Fc region" refers to a polypeptide comprising the constant region of a complete antibody, excluding the CH1 domain and, in some cases, part of the hinge, in either monomeric or multimeric form. The original immunoglobulin source of the natural Fc is preferably human, and can be any immunoglobulin, for example, IgG1, IgG2, IgG3, or IgG4. The natural Fc is composed of monomeric polypeptides that can be linked into dimer or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent associations. The Fc region of an immunoglobulin generally comprises the C1 domain of the heavy chain constant region. H 2 domains and C H 3 domains, and optionally including C H 4 domains.
[0145] In some embodiments, each of the two Fc monomers in the Fc dimer comprises an amino acid substitution that promotes heterodimerization of the two monomers. In some embodiments, heterodimerization of the Fc monomers can be promoted by introducing different but compatible substitutions such as "knob-into-hole" residue pairs into the two Fc monomers. The "knob-into-hole" technology is also disclosed in U.S. Patent Publication No. 8,216,805. In some embodiments, one Fc monomer comprises a knob mutation T366W, and the other Fc monomer comprises a hole mutation T366S, L358A, and Y407V. In some embodiments, two Cys residues (S354C on the "knob" side and Y349C on the "hole" side) that form a stabilized disulfide bridge are introduced.
[0146] The term "Fc receptor" or "FcR" is used to describe a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR described herein is an FcR that binds to an IgG antibody (a gamma receptor), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (activating receptor) and FcγRIIB (inhibiting receptor), which have similar amino acid sequences and differ primarily in the cytoplasmic domain. The cytoplasmic domain of the activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM). The cytoplasmic domain of the inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) (see M.in Annu. Rev. Immunol. 15:203-234 (1997). The term also includes allotypes, such as the FcγRIIIA allotypes: FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131, and / or FcγRIIA-H131. FcRs are described in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991), Capel et al., Immunomethods 4:25-34 (1994), and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). The term FcR in this application encompasses other types of FcRs, including those identified in the future. The term FcR also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgGs to the newborn (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).
[0147] The term "FcRn" refers to the neonatal Fc receptor (FcRn). FcRn is structurally similar to the major histocompatibility complex (MHC) and consists of an α chain non-covalently bound to β2 microglobulin. The various functions of the neonatal Fc receptor FcRn are described in Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739-766. FcRn plays an important role in the passive transport of immunoglobulins (IgGs) from mother to newborn and in regulating serum IgG levels. As a salvage receptor, FcRn can bind and transport endocytosed IgGs in their intact form within and between cells, protecting them from the default degradation pathway.
[0148] The "C" of the human IgG heavy chain constant region H The "I domain" typically extends from amino acid position 118 to amino acid position 215 (EU numbering system).
[0149] The "hinge region" is generally defined as extending from Glu 216 to Pro 230 of human IgG1 (Burton, Molec. Immunol. 22: 161-206 (1985)). By placing the first and last cysteine residues that form inter-heavy chain disulfide bonds in the same positions as in IgG1, the hinge regions of other IgG subtypes can be aligned with the IgG1 sequence.
[0150] Human IgG Fc region "C H The "2 domain" usually extends from amino acid position 231 to amino acid position 340. H The 2 domain is unique in that it does not pair closely with another region. Instead, it is located between the two C H Two N-terminally linked branched sugar chains are inserted between the two domains. It is speculated that sugars may serve as a substitute for domain-to-domain pairing to help maintain C H 2 domains are stabilized. Burton, Molec Immunol. 22: 161-206 (1985).
[0151] “C H The 3" domain includes the C-terminal residue extending from the C H The 2 domains (from amino acid 341 to the C-terminus of the antibody sequence, usually amino acid residue 446 or 447 of IgG).
[0152] A "functional Fc fragment" possesses the "effector functions" of a native Fc region sequence. Exemplary "effector functions" include C1q binding; complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and downregulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to be bound to a binding domain (e.g., an antibody variable region) and can be assessed using a variety of experimental methods known in the art.
[0153] Antibodies with IgG Fc variants having "altered" FcR binding affinity or ADCC activity have enhanced or diminished FcR binding activity and / or ADCC activity compared to the parent polypeptide or a polypeptide comprising a native Fc sequence. Fc variants that exhibit "enhanced binding" to an FcR have a higher binding affinity (e.g., a lower apparent Kd or IC50 value) for at least one FcR compared to the parent polypeptide or a polypeptide comprising a native IgG Fc sequence. In some embodiments, the binding ability is enhanced by 3-fold, e.g., 5, 10, 25, 50, 60, 100, 150, 200, or even up to 500-fold, or the binding ability is increased by 25% to 1000%, compared to the parent polypeptide. Fc variants that exhibit "decreased binding" to an FcR have a lower affinity (e.g., a higher apparent Kd or IC50 value) for at least one FcR compared to the parent polypeptide. The binding ability is decreased by 40% or more compared to the parent polypeptide.
[0154] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" is a form of cytotoxicity that refers to the binding of secreted Ig to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages), enabling these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill the target cells using cytotoxins. Antibodies "arm" the cytotoxic cells and are required for this killing. Of the major cell types that mediate ADCC, NK cells express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. The expression of FcRs on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess the ADCC activity of a target molecule, an in vitro ADCC assay can be performed, as described in U.S. Patent Nos. 5,500,362 or 5,821,337. Effector cells suitable for such experiments include peripheral blood mononuclear cells (PBMC) and natural killer cells (NK). Alternatively, or in addition, the ADCC activity of the target molecule can also be assessed in vivo, for example, as described in the animal model disclosed in Clynes et al. PNAS (USA) 95: 652-656 (1998).
[0155] Polypeptides comprising Fc variants exhibit "enhanced ADCC activity" or are capable of more effectively mediating ADCC in the presence of human effector cells, compared to polypeptides comprising wild-type IgG Fc polypeptides or parent polypeptides. When tested in substantially the same quantity as polypeptides comprising wild-type IgG Fc polypeptides (or parent polypeptides), such polypeptides comprising Fc variants are capable of more effectively mediating ADCC, both in vitro and in vivo. Such variants are generally identified using any in vitro ADCC assay known in the art, such as assays or methods for identifying ADCC activity, such as in animal models. In some embodiments, such variants mediate ADCC 5- to 100-fold more efficiently, such as 25- to 50-fold more efficiently, than wild-type Fc (or parent polypeptide).
[0156] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate structural subclass) that binds to the cognate antigen. To assess complement activation, a CDC assay, such as that described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), can be performed. Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding capacity are described in U.S. Patent No. 6,194,551 B1 and WO 99 / 51642. The contents of these patent publications are expressly incorporated herein by reference. See also Idusogie et al. J. Immunol. 164:4178-4184 (2000).
[0157] Unless otherwise indicated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. A nucleotide sequence encoding a protein or RNA may also include introns, for example, a nucleotide sequence encoding a protein may contain introns in some forms.
[0158] The term "operably linked" refers to a functional connection between a regulatory sequence and a heterologous nucleotide sequence, thereby enabling expression of the latter. For example, a first nucleotide sequence is operably linked to a second nucleotide sequence when the first nucleotide sequence is in a functional relationship with the second nucleotide sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, if necessary, can link two protein coding regions in the same reading frame.
[0159] "Homologous" refers to the sequence similarity or sequence homology between two polypeptides or between two nucleic acid molecules. If the same base or amino acid monomer subunit is present at the same position in two compared sequences, for example, adenine is present at the same position in two DNA molecules, then the two DNA molecules are homologous at that position. The percentage homology between two sequences refers to the ratio of the number of matching or homologous positions shared by the two sequences to the total number of positions multiplied by 100. For example, if 6 out of 10 positions in two sequences are matched or homologous, then the homology between the two sequences is 60%. For example, the DNA sequences ATTGCC and TATGGC have 50% homology. Generally speaking, when aligning two sequences, the comparison is performed with the goal of obtaining maximum homology.
[0160] An "effective amount" of an antibody (including a bispecific antibody) or composition disclosed herein is an amount sufficient to achieve a specific purpose. An "effective amount" can be determined empirically and by known methods related to the purpose.
[0161] The term "therapeutically effective amount" refers to an amount of an antibody (including bispecific antibodies) or composition described herein that is effective for "treating" a disease or condition in an individual. This refers to an amount sufficient to reduce or improve the severity and / or duration of the disease or one or more symptoms thereof; prevent the development of the disease, cause regression of symptoms, prevent the recurrence, development, onset, or progression of one or more symptoms associated with the disease, detect the disease, or enhance / improve the prophylactic or therapeutic effect of another therapy (e.g., a prophylactic or therapeutic agent).
[0162] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" refers to a material that is free of biological activity or other undesirable properties, e.g., a material that can be added to a pharmaceutical composition administered to a patient without causing a significant adverse biological reaction, or that does not interact in a deleterious manner with any other component contained in the composition. Pharmaceutically acceptable carriers or excipients preferably meet the required standards for toxicology or manufacturing testing and / or are included in the inactive ingredient guide compiled by the U.S. Food and Drug Administration.
[0163] The embodiments of the present application described herein should be understood to include "consisting of" and / or "consisting essentially of" embodiments.
[0164] In this application, "about" is mentioned as a numerical value or parameter, including (and describing) variations of the value or parameter itself. For example, the description of "about X" includes the description of "X".
[0165] As used herein, reference to a value or parameter "not" generally refers to and describes "other than" a value or parameter. For example, "the method cannot be used to treat type X infection" means that the method is generally used to treat other types of infection except type X.
[0166] As used in this application and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0167] Antibodies that specifically bind to TRAIL
[0168] On the one hand, the application provides antibodies or antigen-binding fragments that specifically bind to TRAIL, which include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibody molecules comprising heavy and / or light chain CDRs as described herein. On the one hand, the antibody or antigen-binding fragment is an antibody separated from the TRAIL antigen. Expected antibodies or antigen-binding fragments that specifically bind to TRAIL include all or fragments of full-length antibodies (such as full-length IgG1, IgG2 or IgG4) that specifically bind to TRAIL, single-chain antibodies that specifically bind to TRAIL, multispecific (such as bispecific) antibodies that bind to TRAIL, immunoconjugates that specifically bind to TRAIL, and so on. In certain embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL is Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody or linear antibody. In some embodiments, an antibody or antigen-binding fragment that specifically binds to TRAIL means that the affinity of the antibody or antigen-binding fragment to TRAIL is at least 10 times greater (including, for example, 10 ... 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 In some embodiments, a non-target is an antigen that is not TRAIL.
[0169] Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation analysis (RIA). Kd values can be determined by methods known in the art, such as surface plasmon resonance (SPR) technology or biolayer interferometry (BLI) technology.
[0170] Although this application has extensively discussed antibodies or antigen-binding fragments that specifically bind to TRAIL that comprise human sequences (e.g., human heavy and light chain variable regions comprising human CDR sequences), non-human antibodies are also contemplated. In some embodiments, non-human antibodies comprise human CDR sequences and non-human framework sequences of antibodies or antigen-binding fragments that specifically bind to TRAIL as described herein. In some embodiments, non-human framework sequences comprise any sequence for generating heavy and / or light chain variable regions using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, cattle (e.g., cattle, bulls, buffaloes), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., marmosets, macaques), etc. In some embodiments, non-human antibodies or antigen-binding fragments that specifically bind to TRAIL comprise antibodies or antigen-binding fragments that specifically bind to TRAIL that are generated by transplanting one or more human CDR sequences described herein into non-human framework sequences (e.g., mouse or chicken framework sequences).
[0171] In certain embodiments, the antibody or Fab that specifically binds to TRAIL binds to an epitope in human TRAIL. In certain embodiments, the antibody or Fab that specifically binds to TRAIL cross-reacts with TRAIL antigens from species other than humans. In certain embodiments, the antibody or Fab that specifically binds to TRAIL is completely specific for human TRAIL and does not cross-react with other non-human species.
[0172] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
[0173] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L, the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0174] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 13-14 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 13-14; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 22-27 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22-27.
[0175] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: (i) V H , comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 22; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 23; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 24; (iv) V H, comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 25 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 25; (v) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 26 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 26; or (vi) V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 27 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 27.
[0176] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
[0177] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
[0178] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 15-21 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 15-21; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs:28-32 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs:28-32.
[0179] In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: (i) V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 28; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 29; (iii) VH , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 29; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 29; (v) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 29; (vi) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 29; (vii) V H, comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 30; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 30; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO:30 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:30; (x) V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO:30 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:30; (xi) V H, comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO:30 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:30; (xii) V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 31; (xiii) V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO:31 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:31; (xiv) V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 31; (xv) V H, comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 31; (xvi) V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO:31 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:31; or (xvii) V H , comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 21; and V L , which comprises the amino acid sequence of SEQ ID NO:32 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO:32.
[0180] In some embodiments, the above amino acid substitutions are limited to the "exemplary substitutions" shown in Table 10 of the present application. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown in Table 10 of the present application.
[0181] In some embodiments, functional epitopes can be resolved by combined alanine scanning. In this process, combined alanine scanning technology can be used to identify amino acids in the TRAIL protein that are necessary for interaction with an antibody or antigen-binding fragment that specifically binds to TRAIL. In some embodiments, the epitope is conformational and can be identified using the crystal structure of an anti-TRAIL antibody bound to the TRAIL protein.
[0182] In some embodiments, the present application provides antibodies or antigen-binding fragments that compete with any of the above-mentioned antibodies or antigen-binding fragments that specifically bind to TRAIL for binding to TRAIL. In some embodiments, antibodies or antigen-binding fragments that can compete with any of the above-mentioned antibodies or antigen-binding fragments that specifically bind to TRAIL for binding to an epitope on TRAIL are provided. In some embodiments, antibodies or antigen-binding fragments that specifically bind to TRAIL are provided, which are combined with a V H and V L The anti-TRAIL antibody molecules bind to the same epitope, wherein the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 13-21, and said V L In some embodiments, an antibody or antigen-binding fragment specifically binding to TRAIL is provided, which is combined with a V H and V L The anti-TRAIL antibody competitively binds to TRAIL, wherein the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 13-21, and said V L Comprising the amino acid sequence shown in any one of SEQ ID NOs: 22-32.
[0183] In some embodiments, competition assays can be used to identify monoclonal antibodies that compete for TRAIL binding with the antibodies or antigen-binding fragments that specifically bind TRAIL described herein. Competition assays can determine whether two antibodies bind to the same epitope by recognizing identical or spatially overlapping epitopes or by competitively inhibiting antigen binding by one antibody. In certain embodiments, such competing antibodies bind to the same epitope as the antibodies described herein. Some exemplary competition assays include, but are not limited to, conventional assays such as those described in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Detailed exemplary methods for resolving epitopes bound by antibodies are described in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ). In some embodiments, each antibody is said to bind to the same epitope if it blocks 50% or more of the binding of the other antibody. In some embodiments, the antibody that competes with the antibody or antigen-binding fragment that specifically binds to TRAIL described herein is a chimeric antibody, a humanized antibody, or a fully human antibody.
[0184] Exemplary antibody sequences that specifically bind to TRAIL are shown in Table 2, Table 3-1, and Table 3-2, wherein CDR numbering is performed according to the Chothia definition. Those skilled in the art will recognize that there are a variety of known algorithms for predicting the position of CDRs and defining the variable regions of antibody light and heavy chains. H and / or V L Sequences, but based on prediction algorithms other than those exemplified in the table below, are also within the scope of this application.
[0185] Full-length antibody that specifically binds to TRAIL
[0186] In some embodiments, the antibody that specifically binds to TRAIL is a full-length antibody. In some embodiments, the full-length antibody that specifically binds to TRAIL is IgA, IgD, IgE, IgG, or IgM. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the full-length antibody that specifically binds to TRAIL comprises an IgG constant region, such as a constant region of IgG1, IgG2, IgG3, IgG4, or a variant thereof. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an IgG1-type heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an IgG2-type heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an IgG3-type heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an IgG4-type heavy chain constant region. In some embodiments, the IgG is a human IgG. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises a kappa light chain constant region. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 98. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises a lambda light chain constant region. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 99. In some embodiments, the antibody or antigen-binding fragment that specifically binds to TRAIL comprises an antibody heavy chain variable region and an antibody light chain variable region. In some embodiments, the full-length antibody that specifically binds to TRAIL comprises an altered or otherwise modified Fc sequence such that it has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions.
[0187] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1, IgG2, IgG3, or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: a) a heavy chain variable region comprising: HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-2 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 3-4 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 5-6 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and b) a light chain variable region comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NOs: NOs: 7-8 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; LC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 9-10 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and LC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 11-12 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG2 is a human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0188] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1, IgG2, IgG3, or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: a) a heavy chain variable region comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-2, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 3-4, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 5-6, or a variant of the heavy chain variable region comprising up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acid substitutions in its HC-CDR sequence; and b) a light chain variable region comprising: an LC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 7-8, an LC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 9-10, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NOs: The amino acid sequence shown in any one of NOs: 11-12, or a variant of the light chain variable region, comprises a substitution of up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acids in its LC-CDR sequence. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98.In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0189] In some embodiments, a full-length antibody that specifically binds to TRAIL is provided, comprising an IgG1 or IgG4 constant region, wherein the antibody that specifically binds to TRAIL comprises: a) a heavy chain variable region comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and b) a light chain variable region comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0190] In some embodiments, a full-length antibody that specifically binds to TRAIL is provided, comprising an IgG1 or IgG4 constant region, wherein the antibody that specifically binds to TRAIL comprises: a) a heavy chain variable region comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and b) a light chain variable region comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0191] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: a) a heavy chain variable region comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 13-21, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 13-21; and b) a light chain variable region comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 22-32, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 22-32. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:99.
[0192] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H, comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , which comprises the amino acid sequence of SEQ ID NO: 22 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 22. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0193] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, which comprises the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 23. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0194] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, which comprises the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 24. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0195] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, which comprises the amino acid sequence of SEQ ID NO: 25 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 25. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0196] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, which comprises the amino acid sequence of SEQ ID NO: 26 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0197] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L, which comprises the amino acid sequence of SEQ ID NO: 27 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 27. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0198] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L, which comprises the amino acid sequence of SEQ ID NO: 28 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 28. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0199] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L, which comprises the amino acid sequence of SEQ ID NO: 29 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0200] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L, which comprises the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0201] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L, which comprises the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0202] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L, which comprises the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0203] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L, which comprises the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0204] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L, which comprises the amino acid sequence of SEQ ID NO: 30 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0205] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L, which comprises the amino acid sequence of SEQ ID NO: 30 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0206] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L, which comprises the amino acid sequence of SEQ ID NO: 30 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0207] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L, which comprises the amino acid sequence of SEQ ID NO: 30 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0208] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L, which comprises the amino acid sequence of SEQ ID NO: 30 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0209] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0210] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0211] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0212] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0213] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0214] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L, which comprises the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 31. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0215] In some embodiments, a full-length antibody that specifically binds to TRAIL comprising an IgG1 or IgG4 constant region is provided, wherein the antibody that specifically binds to TRAIL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 21; and V L, which comprises the amino acid sequence of SEQ ID NO: 32 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 32. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 96 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 98. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 97 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99.
[0216] Antibodies that specifically bind to FasL
[0217] In some embodiments, the antibodies or antigen-binding fragments that specifically bind to FasL include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibody molecules comprising heavy and / or light chain CDRs as described herein. In one aspect, the antibodies or antigen-binding fragments are isolated antibodies that bind to FasL. Antibodies or antigen-binding fragments that specifically bind to FasL include, in whole or in part, full-length antibodies (e.g., full-length IgG1, IgG2, or IgG4) that specifically bind to FasL, single-chain antibodies that specifically bind to FasL, multispecific (e.g., bispecific) antibodies that bind to FasL, immunoconjugates that specifically bind to FasL, and the like. In some embodiments, the antibody that specifically binds to FasL is Fab, Fab', F(ab)'2, Fab'-SH, single-chain antibody (scFv), Fv fragment, dAb, Fd, nanobody, or diabody. In some embodiments, an antibody or antigen-binding fragment that specifically binds to FasL refers to an antibody or antigen-binding fragment that binds to FasL with an affinity that is at least 10 times greater (including, for example, 10 ... 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 In some embodiments, a non-target is an antigen that is not FasL.
[0218] Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation analysis (RIA). Kd values can be determined by methods known in the art, such as surface plasmon resonance (SPR) technology or biolayer interferometry (BLI) technology.
[0219] Although this application generally discusses antibodies or antigen-binding fragments comprising human sequences (e.g., human heavy and light chain variable regions comprising human CDR sequences), non-human antibodies or antigen-binding fragments are also contemplated. In some embodiments, non-human antibodies or antigen-binding fragments comprise human CDR sequences and non-human framework sequences of the antibodies or antigen-binding fragments described herein. In some embodiments, non-human framework sequences comprise any sequence used to generate heavy and / or light chain variable regions using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, cattle (e.g., cattle, bulls, buffaloes), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., marmosets, macaques), etc. In some embodiments, non-human antibodies or antigen-binding fragments comprise antibodies or antigen-binding fragments produced by grafting one or more human CDR sequences described herein into non-human framework sequences (e.g., mouse or chicken framework sequences).
[0220] In some embodiments, the antibodies or antigen-binding fragments that specifically bind to FasL described herein bind to an epitope in human FasL. In some embodiments, the antibodies or antigen-binding fragments that specifically bind to FasL are completely specific for human FasL and do not cross-react with species or other non-FasL species. In some embodiments, the antibodies or antigen-binding fragments that specifically bind to FasL cross-react with TRAIL antigens from species other than human.
[0221] In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an IgG1 heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an IgG2 heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an IgG3 heavy chain constant region. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an IgG4 heavy chain constant region. In some embodiments, the IgG is human IgG. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:96. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:97. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises a kappa light chain constant region. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:98. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises a lambda light chain constant region. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 99. In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL comprises an antibody heavy chain variable region and an antibody light chain variable region. In some embodiments, the full-length antibody that specifically binds to FasL comprises an altered or otherwise modified Fc sequence such that it has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions.
[0222] In some embodiments, the antibody or antigen-binding fragment that specifically binds to FasL can be selected from the antibodies that specifically bind to FasL described in PCT application PCT / CN2023 / 072293.
[0223] Bispecific antibodies that specifically bind to TRAIL and FasL
[0224] In one aspect, the present application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL and a second antigen-binding domain that specifically binds to FasL. In some embodiments, the bispecific antibody is capable of binding to either TRAIL or FasL. In other preferred embodiments, the bispecific antibody is capable of binding to both TRAIL and FasL. In other more preferred embodiments, the bispecific antibody is capable of binding to both TRAIL and FasL simultaneously.
[0225] In some embodiments, the present application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL, and a second antigen-binding domain that specifically binds to FasL, wherein the first antigen-binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; or (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 161, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the second antigen binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0226] In some embodiments, the present application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL, and a second antigen-binding domain that specifically binds to FasL, wherein the second antigen-binding domain comprises: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or (ii) V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or (iii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.
[0227] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L Contains LCDR1, LCDR2 and LCDR3.
[0228] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L Contains LCDR1, LCDR2 and LCDR3.
[0229] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 164 Hcomprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 168 L Contains LCDR1, LCDR2 and LCDR3.
[0230] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 166 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 170 L Contains LCDR1, LCDR2 and LCDR3.
[0231] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 73 L Contains LCDR1, LCDR2 and LCDR3.
[0232] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 66 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 76 L Contains LCDR1, LCDR2 and LCDR3.
[0233] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , which comprises V as shown in the amino acid sequence SEQ ID NO: 163 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 167 L Contains LCDR1, LCDR2 and LCDR3.
[0234] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H, which comprises V as shown in the amino acid sequence SEQ ID NO: 165 H comprising HCDR1, HCDR2 and HCDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 169 L Contains LCDR1, LCDR2 and LCDR3.
[0235] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , the V H comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 13-20, 33-40, 164 and 166, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 13-20, 33-40, 164 and 166; and V L , the V L Comprising the amino acid sequence shown in any one of SEQ ID NOs: 22-31, 41-50, 168 and 170 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22-31, 41-50, 168 and 170.
[0236] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 13 and 33, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 13 and 33; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41.
[0237] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42.
[0238] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43.
[0239] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 25 and 44 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 25 and 44.
[0240] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 26 and 45 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 26 and 45.
[0241] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 27 and 46 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 27 and 46.
[0242] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 15 and 35, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 15 and 35; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47.
[0243] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 16 and 36, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 16 and 36; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48.
[0244] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 17 and 37, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 17 and 37; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48.
[0245] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 18 and 38, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 18 and 38; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48.
[0246] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 19 and 39, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 19 and 39; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48.
[0247] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 20 and 40, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 20 and 40; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 29 and 48.
[0248] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 16 and 36, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 16 and 36; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49.
[0249] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 17 and 37, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 17 and 37; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49.
[0250] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 18 and 38, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 18 and 38; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49.
[0251] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 19 and 39, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 19 and 39; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49.
[0252] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 20 and 40, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 20 and 40; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49.
[0253] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 16 and 36, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 16 and 36; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50.
[0254] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 17 and 37, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 17 and 37; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50.
[0255] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 18 and 38, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 18 and 38; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50.
[0256] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 19 and 39, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 19 and 39; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50.
[0257] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 20 and 40, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 16 and 36; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50.
[0258] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H, comprising the amino acid sequence of SEQ ID NO: 164 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 164; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 168 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in SEQ ID NO: 168.
[0259] In some embodiments, the first antigen binding domain that specifically binds TRAIL comprises: H , comprising the amino acid sequence of SEQ ID NO: 166 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 166; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 170 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in SEQ ID NO: 170.
[0260] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 63-72, 80-88, 163 and 165, or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 63-72, 80-88, 163 and 165; and V L , the V L The invention also relates to a polypeptide comprising an amino acid sequence as shown in any one of SEQ ID NOs: 73-79, 89-95, 167 and 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 73-79, 89-95, 167 and 169.
[0261] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H, comprising the amino acid sequence of any one of SEQ ID NOs: 63 and 80, or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63 and 80; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs:73 and 89 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs:73 and 89.
[0262] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 64 and 81; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90.
[0263] In some embodiments, the second antigen binding domain that specifically binds FasL comprises: H , comprising the amino acid sequence of any one of SEQ ID NOs: 65 and 81 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 65 and 81; and V L ,...
Claims
1. An isolated antibody or antigen-binding fragment that specifically binds to TRAIL, wherein the antibody or antigen-binding fragment comprises: V H , the V H Include: HC-CDR1, comprising the amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3, which comprises the amino acid sequence SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Include: LC-CDR1, comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3, which comprises the amino acid sequence SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
2. An isolated antibody or antigen-binding fragment that specifically binds to TRAIL, wherein the antibody or antigen-binding fragment comprises: V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 13 H Contains HC-CDR1, HC-CDR2, and HC-CDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 22 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
3. The isolated antibody or antigen-binding fragment that specifically binds to TRAIL according to claim 1 or 2, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 22; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23; (iii)V H , which comprises the amino acid sequence SEQ ID NO: 14 or a variant thereof, wherein the variant is identical to the amino acid sequence SEQ ID NO: 14 has at least about 80% sequence identity; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 25 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 25; (v)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 26 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 26; or (vi)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 27 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
27.
4. An isolated antibody or antigen-binding fragment that specifically binds TRAIL, wherein the antibody or antigen-binding fragment comprises: V H , the V H Include: HC-CDR1, comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3, which comprises the amino acid sequence SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Include: LC-CDR1, comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3, which comprises the amino acid sequence SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
5. An isolated antibody or antigen-binding fragment that specifically binds TRAIL, wherein the antibody or antigen-binding fragment comprises: V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 15 H Contains HC-CDR1, HC-CDR2, and HC-CDR3; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 28 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.
6. The isolated antibody or antigen-binding fragment that specifically binds to TRAIL according to claim 4 or 5, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 28; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 29; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 29; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 29; (v)V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 29; (vi)V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 29 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 29 identity; (vii)V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; (viii)V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; (ix)V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; (x)V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; (xi)V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; (xii)V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; (xiii)V H , comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 17; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; (xiv)V H , comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 18; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; (xv)V H , comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 19; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; (xvi)V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; or (xvii)V H , comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 21; and V L , comprising the amino acid sequence of SEQ ID NO: 32 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
32.
7. An isolated antibody or antigen-binding fragment that specifically binds TRAIL according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment comprises an Fc fragment.
8. The isolated antibody or antigen-binding fragment that specifically binds to TRAIL according to claim 7, wherein the antibody or antigen-binding fragment is a full-length IgG antibody.
9. The isolated antibody or antigen-binding fragment that specifically binds to TRAIL according to claim 8, wherein the antibody or antigen-binding fragment is a full-length IgG1, IgG2, IgG3 or IgG4 antibody.
10. An isolated antibody or antigen-binding fragment that specifically binds TRAIL according to any one of claims 1 to 9, wherein the antibody or antigen-binding fragment is a chimeric, humanized or fully human antibody.
11. An isolated antibody or antigen-binding fragment that specifically binds to TRAIL according to any one of claims 1 to 6, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab)'2, Fab'-SH, single-chain antibody (scFv), Fv fragment, dAb, Fd, nanobody, diabody and linear antibody.
12. A bispecific antibody comprising a first antigen-binding domain that specifically binds to TRAIL and a second antigen-binding domain that specifically binds to FasL.
13. The bispecific antibody according to claim 12, wherein the first antigen binding domain comprises: (i)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L Include: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; or (ii)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L Include: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; or (iii)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 161, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L Include: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO:8, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO:10, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:
12.
14. The bispecific antibody according to claim 12 or 13, wherein the first antigen binding domain comprises: (i)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 13 and 33 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 13 and 33; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 22 and 41; (ii)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42; (iii)V H , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant is The amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 has at least about 80% sequence identity; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43; (iv)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47; (v)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 20 and 40; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 30 and 49; (vi)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; (vii)V H , comprising the amino acid sequence of SEQ ID NO: 164 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 164; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 168 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 168; or (viii)V H , comprising the amino acid sequence of SEQ ID NO: 166 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 166; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 170 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
170.
15. The bispecific antibody according to any one of claims 12 to 14, wherein the second antigen binding domain comprises: (i)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L Include: LC-CDR1 comprises the amino acid sequence of SEQ ID NO: 57, and LC-CDR2 comprises the amino acid sequence SEQ ID NO:59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:61; or (ii)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L Include: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or (iii)V H , the V H Include: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L Include: LC-CDR1, which comprises the amino acid sequence of SEQ ID NO: 162, LC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 60, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO:
62.
16. The bispecific antibody according to any one of claims 12 to 15, wherein the second antigen binding domain comprises: (i)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 63 and 80 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 63 and 80; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 73 and 89 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 73 and 89; (ii)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90; (iii)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92; (iv)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 70 and 86; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 or a variant thereof, wherein the variant is The amino acid sequence shown in any one of SEQ ID NOs: 78 and 94 has at least about 80% sequence identity; (v)V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; (vi)V H , comprising the amino acid sequence of SEQ ID NO: 163 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 163; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 167 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 167; or (vii)V H , comprising the amino acid sequence of SEQ ID NO: 165 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 165; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
169.
17. The bispecific antibody according to any one of claims 12 to 13 or 15, wherein: a) The first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; b) the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; c) the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; d) the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or e) the first antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 161, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC- CDR3 comprising the amino acid sequence of SEQ ID NO: 12; and wherein the second antigen binding domain comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62.
18. The bispecific antibody according to any one of claims 12 to 17, wherein: a) The first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 23 and 42; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90; b) the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 14 and 34; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 24 and 43; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64 and 81; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 74 and 90; c) the first antigen binding domain comprises: V H , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 15 and 35 or a variant thereof, wherein the variant has at least less than about 80% sequence identity; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 28 and 47; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92; d) the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 66 and 82; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 76 and 92; e) the first antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 16 and 36; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 31 and 50; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 69 and 85; and V L , comprising the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 79 and 95; f) the first antigen binding domain comprises: V H , which comprises the amino acid sequence shown in SEQ ID NO: 164 or a variant thereof The variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 164; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 168 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 168; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence of SEQ ID NO: 163 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 163; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 167 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 167; or g) the first antigen binding domain comprises: V H , comprising the amino acid sequence set forth in SEQ ID NO: 166 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 166; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 170 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 170; and wherein the second antigen binding domain comprises: V H , comprising the amino acid sequence of SEQ ID NO: 165 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 165; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 169 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:
169.
19. The bispecific molecule of any one of claims 12-18, comprising an Fc selected from the Fc of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.
20. The bispecific molecule of claim 19, wherein the Fc comprises an Fc variant.
21. The bispecific molecule of claim 20, wherein the Fc variant comprises a substitution at one or more of positions 228, 239, 282, 289, 297, 312, 324, 330, 335, 337, 339, 356, 359, 361, 383, 384, 398, 400, 440, 422, and 442, as numbered according to the EU index.
22. The bispecific molecule of any one of claims 19-21, wherein the Fc region is glycosylated.
23. The bispecific molecule of any one of claims 19-21, wherein the Fc region is aglycosylated.
24. The bispecific molecule of any one of claims 19-23, wherein the Fc region is reduced fucosylated or afucosylated.
25. The bispecific antibody according to any one of claims 12 to 24, wherein the structure thereof is selected from DVD-IgG, Bs4Ab, Hetero H, CrossMab, IgG-(scFv)2, or scFv-Fab IgG.
26. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: The two polypeptide chains contain V from N-terminus to C-terminus. H 1-LV H 2-C H 1 structure, where V H 1 is a specific binding The heavy chain variable region of TRAIL; V H 2 is the heavy chain variable region that specifically binds to FasL; L is the connecting peptide; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and The other two polypeptide chains contain V L 1-LV L 2-C L structure, where V L 1 is the light chain variable region that specifically binds to TRAIL; V L 2 is the light chain variable region that specifically binds to FasL; L is the connecting peptide; C L is the light chain constant region.
27. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: Both polypeptide chains contain V H 1-LV H 2-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; V H 2 is the heavy chain variable region that specifically binds to TRAIL; L is the connecting peptide; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and The other two polypeptide chains contain V L 1-LV L 2-C L structure, where V L 1 is the light chain variable region that specifically binds to FasL; V L 2 is the light chain variable region that specifically binds to TRAIL; L is the connecting peptide; C L is the light chain constant region.
28. The bispecific antibody according to any one of claims 26-27, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 104 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and / or The amino acid sequence of SEQ ID NO: 105 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105; b) the amino acid sequence of SEQ ID NO: 104 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and / or The amino acid sequence of SEQ ID NO: 106 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106; c) the amino acid sequence of SEQ ID NO: 107 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and / or the amino acid sequence of SEQ ID NO: 108 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; d) the amino acid sequence of SEQ ID NO: 107 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and / or The amino acid sequence of SEQ ID NO: 109 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109; e) the amino acid sequence of SEQ ID NO: 110 or a variant thereof, said variant having the same amino acid sequence as SEQ ID NO: 110 have at least about 80% sequence identity; and / or The amino acid sequence of SEQ ID NO: 111 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 111; or f) the amino acid sequence of SEQ ID NO: 172 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 172; and / or The amino acid sequence of SEQ ID NO: 174 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 174).
29. The bispecific antibody according to any one of claims 26-27, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 131 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and / or The amino acid sequence of SEQ ID NO: 105 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105; b) the amino acid sequence of SEQ ID NO: 131 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and / or The amino acid sequence of SEQ ID NO: 106 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106; c) the amino acid sequence of SEQ ID NO: 132 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132; and / or the amino acid sequence of SEQ ID NO: 108 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; d) the amino acid sequence of SEQ ID NO: 132 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132; and / or The amino acid sequence of SEQ ID NO: 109 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109; e) the amino acid sequence of SEQ ID NO: 133 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 133; and / or The amino acid sequence of SEQ ID NO: 111 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 111; or f) the amino acid sequence of SEQ ID NO: 176 or a variant thereof, said variant having the same amino acid sequence as SEQ ID NO: 176 have at least about 80% sequence identity; and / or The amino acid sequence of SEQ ID NO: 174 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:
174.
30. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: The two polypeptide chains contain V from N-terminus to C-terminus H 1-C H 1-L1-V H 2-L3-V L 2 structure or V H 1-C H 1-L1-V L 2-L3-V H 2 structure, where V H 1 is the heavy chain variable region that specifically binds to TRAIL; V H 2 is the heavy chain variable region that specifically binds to FasL, V L 2 is the light chain variable region that specifically binds to FasL; L1 and L3 are connecting peptides; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and The other two polypeptide chains contain V L 1-C L structure, where V L 1 is the light chain variable region that specifically binds to TRAIL, C L is the light chain constant region.
31. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: The two polypeptide chains contain V from N-terminus to C-terminus H 1-C H 1-L1-V H 2-L3-V L 2 structure or V H 1-C H 1-L1-V L 2-L3-V H 2 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; V H 2 is the heavy chain variable region that specifically binds to TRAIL, V L 2 is the light chain variable region that specifically binds to TRAIL; L1 and L3 are connecting peptides; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and The other two polypeptide chains contain V L 1-C L structure, where V L 1 is the light chain variable region that specifically binds to FasL, C L is the light chain constant region.
32. The bispecific antibody according to any one of claims 30-31, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 112 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 112; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; b) the amino acid sequence of SEQ ID NO: 114 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 114; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; c) the amino acid sequence of SEQ ID NO: 116 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 116; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; d) the amino acid sequence of SEQ ID NO: 117 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 117; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; e) the amino acid sequence of SEQ ID NO: 118 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 118; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; f) the amino acid sequence of SEQ ID NO: 120 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and / or the amino acid sequence of SEQ ID NO: 121 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121; g) the amino acid sequence of SEQ ID NO: 120 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and / or the amino acid sequence of SEQ ID NO: 122 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; h) the amino acid sequence of SEQ ID NO: 123 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 123; and / or the amino acid sequence of SEQ ID NO: 124 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 124; or i) the amino acid sequence of SEQ ID NO: 171 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 171; and / or the amino acid sequence of SEQ ID NO: 173 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:
173.
33. The bispecific antibody according to any one of claims 30-31, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 134 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 134; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; b) the amino acid sequence of SEQ ID NO: 135 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 135; and / or the amino acid sequence of SEQ ID NO: 113 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 113; c) the amino acid sequence of SEQ ID NO: 136 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 136; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; d) the amino acid sequence of SEQ ID NO: 137 or a variant thereof, said variant having the same amino acid sequence as SEQ ID NO: 137 having at least about 80% sequence identity; and / or the amino acid sequence of SEQ ID NO: 115 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 115; e) the amino acid sequence of SEQ ID NO: 138 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 138; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; f) the amino acid sequence of SEQ ID NO: 139 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 139; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; g) the amino acid sequence of SEQ ID NO: 140 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 140; and / or the amino acid sequence of SEQ ID NO: 119 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119; h) the amino acid sequence of SEQ ID NO: 141 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141; and / or the amino acid sequence of SEQ ID NO: 121 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121; i) the amino acid sequence of SEQ ID NO: 141 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141; and / or the amino acid sequence of SEQ ID NO: 122 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; j) the amino acid sequence of SEQ ID NO: 142 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 142; and / or the amino acid sequence of SEQ ID NO: 124 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 124; or k) the amino acid sequence of SEQ ID NO: 175 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 175; and / or the amino acid sequence of SEQ ID NO: 173 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:
173.
34. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: One of the polypeptide chains contains V from N-terminus to C-terminus H 1-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to TRAIL, C H 1 is the heavy chain constant region C H 1 domain, wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and A polypeptide chain from N-terminus to C-terminus contains V L 1-C L , where V L 1 is the light chain variable region that specifically binds to TRAIL, C L is the light chain constant region; and A polypeptide chain from N-terminus to C-terminus contains V H 2-C L , where V H 2 is the heavy chain variable region that specifically binds to FasL, C L is a light chain constant region, wherein the polypeptide chain further comprises an Fc comprising a C H 2 and C H 3 domains; and A polypeptide chain from N-terminus to C-terminus contains V L 2-C H 1, where V L 2 is the light chain variable region that specifically binds to FasL, C H 1 is the heavy chain constant region C H 1 domain.
35. The bispecific antibody according to any one of claims 12 to 25, comprising four polypeptide chains: A polypeptide chain from N-terminus to C-terminus contains V H 1-C H 1 structure, where V H 1 is the heavy chain variable region that specifically binds to FasL; C H 1 is the heavy chain constant region C H 1 domain; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and A polypeptide chain from N-terminus to C-terminus contains V L 1-C L , where V L 1 is the light chain variable region that specifically binds to FasL, C L is the light chain constant region; and A polypeptide chain from N-terminus to C-terminus contains V H 2-C L , where V H 2 is the heavy chain variable region that specifically binds to TRAIL; C L is a light chain constant region; wherein the polypeptide chain further comprises an Fc, the Fc comprising a C H 2 and C H 3 domains; and A polypeptide chain from N-terminus to C-terminus contains V L 2-C H 1, where V L 2 is the light chain variable region that specifically binds to TRAIL, C H 1 is the heavy chain constant region C H 1 domain.
36. The bispecific antibody according to any one of claims 34-35, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 125 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and / or The amino acid sequence of SEQ ID NO: 126 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and / or The amino acid sequence of SEQ ID NO: 127 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 127; and / or The amino acid sequence of SEQ ID NO: 129 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129; or b) the amino acid sequence of SEQ ID NO: 125 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 125; and / or The amino acid sequence of SEQ ID NO: 130 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130; and / or The amino acid sequence of SEQ ID NO: 128 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 128; and / or The amino acid sequence of SEQ ID NO: 129 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:
129.
37. The bispecific antibody according to any one of claims 34-35, wherein the bispecific antibody comprises: a) the amino acid sequence of SEQ ID NO: 143 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 143; and / or The amino acid sequence of SEQ ID NO: 126 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 126; and / or The amino acid sequence of SEQ ID NO: 144 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 144; and / or The amino acid sequence of SEQ ID NO: 129 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 129; or b) the amino acid sequence of SEQ ID NO: 145 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 145; and / or The amino acid sequence of SEQ ID NO: 130 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 130; and / or The amino acid sequence of SEQ ID NO: 146 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 146; and / or The amino acid sequence of SEQ ID NO: 129 or a variant thereof, wherein the variant has at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:
129.
38. A nucleic acid molecule encoding the antibody or antigen-binding fragment that specifically binds to TRAIL according to any one of claims 1-11, or the bispecific antibody according to any one of claims 12-37.
39. A vector comprising the nucleic acid molecule of claim 38.
40. An isolated host cell comprising the antibody or antigen-binding fragment that specifically binds to TRAIL according to any one of claims 1-11, or the bispecific antibody according to any one of claims 12-37, the nucleic acid molecule according to claim 38, or the vector according to claim 39.
41. A method for preparing the antibody or antigen-binding fragment that specifically binds to TRAIL according to any one of claims 1 to 11, or the bispecific antibody according to any one of claims 12 to 37, comprising: a) culturing the host cell of claim 40 under conditions effective to express the antibody; and b) obtaining the expressed antibody from the host cell.
42. A pharmaceutical composition comprising the antibody or antigen-binding fragment that specifically binds to TRAIL according to any one of claims 1-11, the bispecific antibody according to any one of claims 12-37, the nucleic acid molecule according to claim 38, the vector according to claim 39, the isolated host cell according to claim 40, or the antibody prepared by the method according to claim 41, and a pharmaceutically acceptable carrier or excipient.
43. A method for treating a disease or condition in an individual in need thereof, the method comprising administering to the individual an effective amount of an antibody or antigen-binding fragment that specifically binds to TRAIL as described in any one of claims 1-11, a bispecific antibody as described in any one of claims 12-37, a nucleic acid molecule as described in claim 38, a vector as described in claim 39, an isolated host cell as described in claim 40, or an antibody produced by the method as described in claim 41, or a pharmaceutical composition as described in claim 42.
44. A pharmaceutical composition comprising: an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL, wherein the antibody or antigen-binding fragment that specifically binds to TRAIL comprises: a)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or b)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
45. A method for treating and / or preventing a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of an antibody or antigen-binding fragment that specifically binds TRAIL and an antibody or antigen-binding fragment that specifically binds FasL, or a pharmaceutical composition comprising the antibody or antigen-binding fragment that specifically binds TRAIL and the antibody or antigen-binding fragment that specifically binds FasL, wherein the antibody or antigen-binding fragment that specifically binds TRAIL comprises: a)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or b)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
46. The pharmaceutical composition of claim 44 or the method of claim 45, wherein the antibody or antigen-binding fragment that specifically binds TRAIL comprises: (i)V H , comprising the amino acid sequence of SEQ ID NO: 13 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and V L , comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 22; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 28; (v)V H , comprising the amino acid sequence of SEQ ID NO: 20 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and V L , comprising the amino acid sequence of SEQ ID NO: 30 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; or (vi)V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
31.
47. The pharmaceutical composition according to any one of claims 44 and 46, or the method according to any one of claims 45-46, wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: a)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or b)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
48. The pharmaceutical composition of any one of claims 44, 46-47, or the method of any one of claims 45-47, wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: (i)V H , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; and V L , comprising the amino acid sequence of SEQ ID NO: 73 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 73; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; or (v)V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
79.
49. A pharmaceutical composition comprising: an antibody or antigen-binding fragment that specifically binds to TRAIL and an antibody or antigen-binding fragment that specifically binds to FasL, wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: a)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or b)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
50. A method for treating and / or preventing a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of an antibody or antigen-binding fragment that specifically binds TRAIL and an antibody or antigen-binding fragment that specifically binds FasL, or a pharmaceutical composition comprising the antibody or antigen-binding fragment that specifically binds TRAIL and the antibody or antigen-binding fragment that specifically binds FasL, wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: a)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L Comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO: 57, LC-CDR2 comprising amino acid sequence SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence SEQ ID NO: 61, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or b)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
51. The pharmaceutical composition of claim 49 or the method of claim 50, wherein the antibody or antigen-binding fragment that specifically binds FasL comprises: (i)V H , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; and V L , comprising the amino acid sequence of SEQ ID NO: 73 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 73; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; or (v)V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
79.
52. The pharmaceutical composition of any one of claims 44, 47, or 49, the method of any one of claims 45, 47, or 50, or the use of any one of claims 46-47, 49-50, or 56-57, wherein: a) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , the V H Contains: HC- CDR1, which comprises the amino acid sequence of SEQ ID NO: 1, HC-CDR2, which comprises the amino acid sequence of SEQ ID NO: 3, and HC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; b) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; c) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , the V H Comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence SEQ ID NO: 3, and HC-CDR3, which comprises the amino acid sequence SEQ ID NO: 5, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L a variant comprising up to about 5 amino acid substitutions in its LC-CDRs; or d) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 8, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 12, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.
53. The pharmaceutical composition according to any one of claims 44, 46-49, or 51, or the method according to any one of claims 45-48, 50-51, wherein: a) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , which comprises the amino acid sequence SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 23 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74; b) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and V L , comprising the amino acid sequence of SEQ ID NO: 24 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; and V L , comprising the amino acid sequence of SEQ ID NO: 74 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74; c) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and V L , comprising the amino acid sequence of SEQ ID NO: 28 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 28; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76; d) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence SEQ ID NO: 66 or a variant thereof, said variant having at least about 80% sequence identity; and V L , comprising the amino acid sequence of SEQ ID NO: 76 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76; e) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and V L , comprising the amino acid sequence of SEQ ID NO: 78 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; or f) an antibody or antigen-binding fragment that specifically binds to TRAIL comprising: V H , comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and V L , comprising the amino acid sequence of SEQ ID NO: 31 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31; And wherein the antibody or antigen-binding fragment that specifically binds to FasL comprises: V H , comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and V L , comprising the amino acid sequence of SEQ ID NO: 79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:
79.
54. The method of any one of claims 45-48, 50-53, wherein the antibody or antigen-binding fragment that specifically binds TRAIL and the antibody or antigen-binding fragment that specifically binds FasL are administered to the individual simultaneously or are administered to the individual sequentially.
55. The method of any one of claims 43, 45-48, 50-53, wherein the disease or condition is an inflammatory disease, autoimmune disease, transplantation-related disease, liver disease, neurodegenerative disease, or cancer associated with the TRAIL and / or FasL signaling pathway.
56. The use or method of claim 55, wherein the disease or condition is selected from transplant rejection, graft-versus-host disease, liver injury, pulmonary hypertension, Alzheimer's disease, acute lung injury, acute respiratory distress syndrome, myocardial infarction, cardiomyopathy, ischemia-reperfusion injury, diabetes, brain injury, spinal cord injury, acute viral hepatitis B, acute viral hepatitis C, chronic hepatitis C, chronic hepatitis B, alcoholic hepatitis, non-alcoholic steatohepatitis, cirrhosis, drug-induced liver injury / failure, autoimmune hepatitis, chronic kidney disease, acute kidney disease, diabetic nephropathy, and cancer.
